<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523417300235</prism:url><dc:identifier>doi:10.1016/j.ejmech.2017.01.015</dc:identifier><eid>1-s2.0-S0223523417300235</eid><prism:doi>10.1016/j.ejmech.2017.01.015</prism:doi><pii>S0223-5234(17)30023-5</pii><dc:title>Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>127</prism:volume><prism:startingPage>493</prism:startingpage><prism:endingPage>508</prism:endingpage><prism:pageRange>493-508</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2017-02-15</prism:coverdate><prism:coverDisplayDate>15 February 2017</prism:coverdisplaydate><prism:copyright>© 2017 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Fang, Yu</dc:creator><dc:creator>Wang, Dawei</dc:creator><dc:creator>Xu, Xingyu</dc:creator><dc:creator>Liu, Jianping</dc:creator><dc:creator>Wu, Aiqin</dc:creator><dc:creator>Li, Xiang</dc:creator><dc:creator>Xue, Qianqian</dc:creator><dc:creator>Wang, Huan</dc:creator><dc:creator>Wang, Hang</dc:creator><dc:creator>Zhang, Huabei</dc:creator><dc:description>
                  Focal adhesion kinase (FAK) is considered as an attractive target for oncology. A series of F-18 labeled 5-bromo-N2-(4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl)-N4-(4-methoxyphenyl)pyrimidine-2,4-diamine derivatives were prepared and evaluated as the FAK targeted radiotracers for the early diagnoses of tumor. For the study of the FAK targeted drug molecules, this was the first attempt to develop the tumor diagnostic imaging agents on the radiopharmaceutical level. They inhibited the activity of FAK with IC50 in the range of 91.4–425.7 nM, and among which the result of the [19F]2 was relatively good and had a modest IC50 of 91.4 nM. The [19F]2 was also profiled in vitro against some other kinds of cancer-related kinases (including two kinds of non-receptor tyrosine kinase: PYK2 and JAK2, and three kinds of receptor tyrosine kinase: IGF-1R, EGFR and PDGFRβ). It displayed 25.2 folds selectivity against PYK2, 35.1 folds selectivity against EGFR, and more than 100 folds selectivity against IGF-1R, JAK2 and PDGFRβ. For the biodistribution in S180 bearing mice, the corresponding [18F]2 were also relatively good, with modest tumor uptake of 5.47 ± 0.19 and 5.80 ± 0.06 %ID/g at 15 and 30 min post-injection, respectively. Furthermore, its tumor/muscle, tumor/bone and tumor/blood ratio at 15 min post-injection were 3.16, 2.53 and 4.52, respectively. And its tumor/muscle, tumor/bone and tumor/blood ratio at 30 min post-injection were 3.14, 2.76 and 4.43, respectively. In addition, coronal micro-PET/CT images of a mouse bearing S180 tumor clearly confirmed that [18F]2 could be accumulated in tumor, especially at 30 min post-injection. Besides, for the [18F]2, both the biodistribution data and the micro-PET/CT imaging study showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC50 value of 1.5 nM) at 1 h before the injection of radiotracer. In combination with the above kinase profiling assay, it could be indicated that the uptake of [18F]2 in tumor of the mouse model was due to FAK expression, and that [18F]2 might be a kind of selectively FAK targeted tumor imaging agents. What's more, the results of the MD (molecular dynamics) simulations were in agreement with the changing trends of the interaction between the different F-19 standards and the FAK (expressed as the in vitro inhibitory abilities of enzymatic activities of FAK in this article), which was also in agreement with and had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>F-18 labeled</dcterms:subject><dcterms:subject>Focal adhesion kinase (FAK)</dcterms:subject><dcterms:subject>Radiotracers</dcterms:subject><dcterms:subject>Tumor imaging</dcterms:subject><dcterms:subject>Molecular dynamics (MD) simulation</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523417300235" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523417300235" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="18103">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="12294">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="196" height="163" size="13339">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="52" height="161" size="10062">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="191" height="164" size="18246">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="140" size="16061">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="164" size="9635">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="167" height="164" size="11782">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="496" height="200" size="50367">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="662" size="101301">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="669" size="108384">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="313" height="970" size="73753">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="575" size="105919">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="802" height="512" size="118784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="291" size="31391">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="570" size="56836">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2198" height="886" size="290935">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="2929" size="590858">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="2962" size="588170">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1386" height="4297" size="535046">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="2546" size="695335">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3551" height="2267" size="760765">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="1289" size="143740">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2567" height="2521" size="325706">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="6957568">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-mmc1.doc?httpAccept=%2A%2F%2A</object><object ref="si1" category="thumbnail" type="ALTIMG" multimediatype="GIF image file" mimetype="image/gif" width="185" height="75" size="1523">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-si1.gif?httpAccept=%2A%2F%2A</object><object ref="si2" category="thumbnail" type="ALTIMG" multimediatype="GIF image file" mimetype="image/gif" width="599" height="142" size="8335">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523417300235-si2.gif?httpAccept=%2A%2F%2A</object></objects><scopus-id>85009443001</scopus-id><scopus-eid>2-s2.0-85009443001</scopus-eid><pubmed-id>28109944</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85009443001" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20170111">2017-01-11</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20170111">2017-01-11</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20170204">2017-02-04</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20170204">2017-02-04</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2018-01-09T01:12:37</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523417300235</xocs:eid>
      <xocs:pii-formatted>S0223-5234(17)30023-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523417300235</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2017.01.015</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523416X00190</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20180109">2018-01-09T01:47:48.33969Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20170215</xocs:date-search-begin>
      <xocs:year-nav>2017</xocs:year-nav>
      <xocs:indexeddate epoch="1484154666">2017-01-11T17:11:06.547808Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body mmlmath acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>127</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>127</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 127</xocs:vol-iss-suppl-text>
      <xocs:sort-order>42</xocs:sort-order>
      <xocs:first-fp>493</xocs:first-fp>
      <xocs:last-lp>508</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>493</xocs:first-page>
         <xocs:last-page>508</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20170215</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 February 2017</xocs:cover-date-text>
      <xocs:cover-date-start>2017-02-15</xocs:cover-date-start>
      <xocs:cover-date-year>2017</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2017 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>SYNTHESISBIOLOGICALEVALUATIONMOLECULARDYNAMICSMDSIMULATIONSTUDIESTHREENOVELF18LABELEDFOCALADHESIONKINASEFAKTARGETED5BROMOPYRIMIDINESRADIOTRACERSFORTUMOR</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>FANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>Y</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Radiolabeling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vitro stability study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological activity</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.4.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>FAK inhibitory assay of the F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold>, and kinase selectivity profile of the F-19 standard [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.4.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Biodistribution of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1,</ce:bold> [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold> in mice bearing S180 tumor</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.4.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>Micro-PET/CT imaging studies of [</ce:italic>
                     <ce:sup loc="post">
                        <ce:italic>18</ce:italic>
                     </ce:sup>
                     <ce:italic>F]</ce:italic>
                     <ce:bold>2</ce:bold> 
                     <ce:italic>in mice bearing S180 tumor</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular dynamics (MD) simulations</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experiments</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Materials and measurements</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Bromo-2-chloro-<ce:italic>N</ce:italic>-(4-methoxyphenyl)pyrimidin-4-amine <ce:bold>(6)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(4-((5-bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethyl 4-methylbenzenesulfonate <ce:bold>(8a)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(2-(4-((5-bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethoxy)-ethyl 4-methylbenzenesulfonate <ce:bold>(8b)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(2-(2-(4-((5-bromo-4-((4-methoxyphenyl)amino)- pyrimidin-2-yl)amino)phenoxy)ethoxy)-ethoxy)ethyl 4-methylbenzenesulfonate <ce:bold>(8c)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-fluoroethoxy)phenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxy- <ce:italic>phenyl)pyrimidine-2,4-diamine</ce:italic> ([<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-(2-fluoroethoxy)ethoxy)phenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxyphenyl)pyrimidine-2,4-diamine <ce:bold>(</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>2)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)phenyl)<ce:italic>N</ce:italic>
                     <ce:sup loc="post">
                        <ce:italic>4</ce:italic>
                     </ce:sup>
                     <ce:italic>-(4-methoxyphenyl)-pyrimidine-2,4-diamine</ce:italic> 
                     <ce:bold>(</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>3)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Radiolabeling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Partition coefficient determination <ce:cross-ref refid="bib64" id="crosref0310">[64]</ce:cross-ref>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vitro stability studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>FAK inhibitory assay and biochemical assay for kinase selectivity profiling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biodistribution studies and micro-PET/CT imaging studies in S180-tumor-bearing mice <ce:cross-ref refid="bib65" id="crosref0320">[65]</ce:cross-ref>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Virtual calculation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.8.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Preparation of the initial conformations of ligands for the MD simulations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.8.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>MD simulations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Compliance with ethical standards</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Author contributions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Conflicts of interest</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>SCHALLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>5192</xocs:ref-first-fp>
            <xocs:ref-last-lp>5196</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>HANKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>8487</xocs:ref-first-fp>
            <xocs:ref-last-lp>8491</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>HALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>185</xocs:ref-first-fp>
            <xocs:ref-last-lp>225</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>PENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>52</xocs:ref-first-fp>
            <xocs:ref-last-lp>67</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>HOCHWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>26</xocs:ref-first-fp>
            <xocs:ref-last-lp>35</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>SCHLAEPFER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>92</xocs:ref-first-fp>
            <xocs:ref-last-lp>101</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>MITRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>56</xocs:ref-first-fp>
            <xocs:ref-last-lp>68</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>PARSONS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1409</xocs:ref-first-fp>
            <xocs:ref-last-lp>1416</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>DAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>237</xocs:ref-first-fp>
            <xocs:ref-last-lp>251</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>LIETHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>e3800</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>ROBERTS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1935</xocs:ref-first-fp>
            <xocs:ref-last-lp>1944</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>DAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4552</xocs:ref-first-fp>
            <xocs:ref-last-lp>4556</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>HEINRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1160</xocs:ref-first-fp>
            <xocs:ref-last-lp>1170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>154</xocs:ref-first-fp>
            <xocs:ref-last-lp>163</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>CANCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LECHERTIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>404</xocs:ref-first-fp>
            <xocs:ref-last-lp>412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>638</xocs:ref-first-fp>
            <xocs:ref-last-lp>642</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>CANCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2417</xocs:ref-first-fp>
            <xocs:ref-last-lp>2423</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>MCLEAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>505</xocs:ref-first-fp>
            <xocs:ref-last-lp>515</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>503</xocs:ref-first-fp>
            <xocs:ref-last-lp>510</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>CHATZIZACHARIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1315</xocs:ref-first-fp>
            <xocs:ref-last-lp>1328</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>681</xocs:ref-first-fp>
            <xocs:ref-last-lp>684</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>VANNIMWEGEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>597</xocs:ref-first-fp>
            <xocs:ref-last-lp>609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>735</xocs:ref-first-fp>
            <xocs:ref-last-lp>741</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>SCHULTZE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>777</xocs:ref-first-fp>
            <xocs:ref-last-lp>788</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>687</xocs:ref-first-fp>
            <xocs:ref-last-lp>706</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>SCHULTZE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>593</xocs:ref-first-fp>
            <xocs:ref-last-lp>599</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>FUJII</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>104</xocs:ref-first-fp>
            <xocs:ref-last-lp>111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>JAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1384</xocs:ref-first-fp>
            <xocs:ref-last-lp>1390</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1256</xocs:ref-first-fp>
            <xocs:ref-last-lp>1259</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>LARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1289</xocs:ref-first-fp>
            <xocs:ref-last-lp>1294</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>OWENS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>2752</xocs:ref-first-fp>
            <xocs:ref-last-lp>2755</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>LIGHTFOOT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>109</xocs:ref-first-fp>
            <xocs:ref-last-lp>116</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>GIAGINIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>173</xocs:ref-first-fp>
            <xocs:ref-last-lp>181</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>GABRIEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1221</xocs:ref-first-fp>
            <xocs:ref-last-lp>1225</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>RECHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>3191</xocs:ref-first-fp>
            <xocs:ref-last-lp>3197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>TAVERNIERTARDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>764</xocs:ref-first-fp>
            <xocs:ref-last-lp>768</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>HECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>2699</xocs:ref-first-fp>
            <xocs:ref-last-lp>2707</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>GUTENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>224</xocs:ref-first-fp>
            <xocs:ref-last-lp>230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>SCHRODER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>361</xocs:ref-first-fp>
            <xocs:ref-last-lp>366</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>JUDSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>1551</xocs:ref-first-fp>
            <xocs:ref-last-lp>1556</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>BEIERLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3299</xocs:ref-first-fp>
            <xocs:ref-last-lp>3305</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>OWENS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>100</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>TREMBLAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>164</xocs:ref-first-fp>
            <xocs:ref-last-lp>171</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>CANEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3272</xocs:ref-first-fp>
            <xocs:ref-last-lp>3279</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SLACKDAVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>14845</xocs:ref-first-fp>
            <xocs:ref-last-lp>14852</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>WALKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>6071</xocs:ref-first-fp>
            <xocs:ref-last-lp>6077</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib48a">
            <xocs:ref-normalized-surname>FRANCOIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>S174</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib48b">
            <xocs:ref-normalized-surname>JONES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib49a">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2173</xocs:ref-first-fp>
            <xocs:ref-last-lp>2176</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib49b">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2689</xocs:ref-first-fp>
            <xocs:ref-last-lp>2692</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>LIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2306</xocs:ref-first-fp>
            <xocs:ref-last-lp>2314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>TANJONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>764</xocs:ref-first-fp>
            <xocs:ref-last-lp>777</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>ZIFICSAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>133</xocs:ref-first-fp>
            <xocs:ref-last-lp>137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>JONES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1100</xocs:ref-first-fp>
            <xocs:ref-last-lp>1107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>AUGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib56a">
            <xocs:ref-normalized-surname>IWATANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-last-lp>60</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib56b">
            <xocs:ref-normalized-surname>TOMITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1779</xocs:ref-first-fp>
            <xocs:ref-last-lp>1785</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>7405</xocs:ref-first-fp>
            <xocs:ref-last-lp>7416</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>KURENOVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4716</xocs:ref-first-fp>
            <xocs:ref-last-lp>4724</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib59a">
            <xocs:ref-normalized-surname>UCAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3250</xocs:ref-first-fp>
            <xocs:ref-last-lp>3259</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib59b">
            <xocs:ref-normalized-surname>UCAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>602</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>532</xocs:ref-first-fp>
            <xocs:ref-last-lp>545</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>GOLUBOVSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>342</xocs:ref-first-fp>
            <xocs:ref-last-lp>346</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1357</xocs:ref-first-fp>
            <xocs:ref-last-lp>1367</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>CUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9283</xocs:ref-first-fp>
            <xocs:ref-last-lp>9296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>QIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4873</xocs:ref-first-fp>
            <xocs:ref-last-lp>4877</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>4736</xocs:ref-first-fp>
            <xocs:ref-last-lp>4741</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>SYBYLVERSIONX13</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>FRISCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>GAUSSIAN09REVISIONB01</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>DUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1999</xocs:ref-first-fp>
            <xocs:ref-last-lp>2012</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>AMBERVERSION10</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>JAKALIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1623</xocs:ref-first-fp>
            <xocs:ref-last-lp>1641</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1157</xocs:ref-first-fp>
            <xocs:ref-last-lp>1174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>JORGENSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1983</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>935</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>RYCKAERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1977</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>341</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>ESSMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>8577</xocs:ref-first-fp>
            <xocs:ref-last-lp>8593</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>5221</xocs:ref-first-fp>
            <xocs:ref-last-lp>5230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>FANGX2017X493</xocs:refkey3>
         <xocs:refkey4lp>FANGX2017X493X508</xocs:refkey4lp>
         <xocs:refkey4ai>FANGX2017X493XY</xocs:refkey4ai>
         <xocs:refkey5>FANGX2017X493X508XY</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2019-02-04T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2017 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(17)30023-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523417300235</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523417300235</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2017.01.015</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2018-01-09T01:47:48.33969Z</xocs:timestamp>
         <xocs:cover-date-start>2017-02-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/MAIN/application/pdf/2b8889d74e579e67351d6a25875a6155/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/MAIN/application/pdf/2b8889d74e579e67351d6a25875a6155/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2460624</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>16</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523417300235-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/PREVIEW/image/png/a8cba71a47f525278d6b24a3abeacf35/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/PREVIEW/image/png/a8cba71a47f525278d6b24a3abeacf35/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>54184</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/fx1/THUMBNAIL/image/gif/32d42ced364d4003526fc3d795e325eb/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/fx1/THUMBNAIL/image/gif/32d42ced364d4003526fc3d795e325eb/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18103</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr1/THUMBNAIL/image/gif/0776ffc19590d61faf6a2acf07689197/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr1/THUMBNAIL/image/gif/0776ffc19590d61faf6a2acf07689197/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12294</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr2/THUMBNAIL/image/gif/cd1d487fd9c538de28f4c509d4e6b44f/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr2/THUMBNAIL/image/gif/cd1d487fd9c538de28f4c509d4e6b44f/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13339</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>196</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr3/THUMBNAIL/image/gif/90651584c2f9982a59d25909249e4c51/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr3/THUMBNAIL/image/gif/90651584c2f9982a59d25909249e4c51/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10062</xocs:filesize>
               <xocs:pixel-height>161</xocs:pixel-height>
               <xocs:pixel-width>52</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr4/THUMBNAIL/image/gif/ffe3233b167bdda5b3fec2b81a924445/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr4/THUMBNAIL/image/gif/ffe3233b167bdda5b3fec2b81a924445/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18246</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>191</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr5/THUMBNAIL/image/gif/43ae7853d301e6bf27368f7c878fe77d/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr5/THUMBNAIL/image/gif/43ae7853d301e6bf27368f7c878fe77d/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16061</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr6/THUMBNAIL/image/gif/0289ddbb70994cc825b948281e6f0458/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr6/THUMBNAIL/image/gif/0289ddbb70994cc825b948281e6f0458/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9635</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/sc1/THUMBNAIL/image/gif/7f1f17e87db267fe250e1ff39cf864c0/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/sc1/THUMBNAIL/image/gif/7f1f17e87db267fe250e1ff39cf864c0/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11782</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>167</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/fx1/DOWNSAMPLED/image/jpeg/81260e0489d76b04580e85cfb80f77aa/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/fx1/DOWNSAMPLED/image/jpeg/81260e0489d76b04580e85cfb80f77aa/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>50367</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>496</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr1/DOWNSAMPLED/image/jpeg/c76adbab66adbb63fba6b91c85507b4d/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr1/DOWNSAMPLED/image/jpeg/c76adbab66adbb63fba6b91c85507b4d/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>101301</xocs:filesize>
               <xocs:pixel-height>662</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr2/DOWNSAMPLED/image/jpeg/217494089adf125fb1b556b426a21b3f/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr2/DOWNSAMPLED/image/jpeg/217494089adf125fb1b556b426a21b3f/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>108384</xocs:filesize>
               <xocs:pixel-height>669</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr3/DOWNSAMPLED/image/jpeg/28f9b47294a450f86eecde2bf88f48b8/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr3/DOWNSAMPLED/image/jpeg/28f9b47294a450f86eecde2bf88f48b8/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>73753</xocs:filesize>
               <xocs:pixel-height>970</xocs:pixel-height>
               <xocs:pixel-width>313</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr4/DOWNSAMPLED/image/jpeg/62c100a204b19174999a190dedbb3b57/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr4/DOWNSAMPLED/image/jpeg/62c100a204b19174999a190dedbb3b57/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>105919</xocs:filesize>
               <xocs:pixel-height>575</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr5/DOWNSAMPLED/image/jpeg/38b817df2266ad4eb07aa3c561ac3f38/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr5/DOWNSAMPLED/image/jpeg/38b817df2266ad4eb07aa3c561ac3f38/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>118784</xocs:filesize>
               <xocs:pixel-height>512</xocs:pixel-height>
               <xocs:pixel-width>802</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr6/DOWNSAMPLED/image/jpeg/b9567882fa7a806ca22c3a64815c4acc/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr6/DOWNSAMPLED/image/jpeg/b9567882fa7a806ca22c3a64815c4acc/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31391</xocs:filesize>
               <xocs:pixel-height>291</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/sc1/DOWNSAMPLED/image/jpeg/84969dad730cd7614ea51653904d8355/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/sc1/DOWNSAMPLED/image/jpeg/84969dad730cd7614ea51653904d8355/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56836</xocs:filesize>
               <xocs:pixel-height>570</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/fx1/HIGHRES/image/jpeg/15b17ecb41b9b3e1836a00f9c06e534c/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/fx1/HIGHRES/image/jpeg/15b17ecb41b9b3e1836a00f9c06e534c/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>290935</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>2198</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr1/HIGHRES/image/jpeg/607083ab468fa6bf8a54c096ea5e7698/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr1/HIGHRES/image/jpeg/607083ab468fa6bf8a54c096ea5e7698/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>590858</xocs:filesize>
               <xocs:pixel-height>2929</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr2/HIGHRES/image/jpeg/050ac8fbf88195a9ff33d6d1aa8db82d/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr2/HIGHRES/image/jpeg/050ac8fbf88195a9ff33d6d1aa8db82d/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>588170</xocs:filesize>
               <xocs:pixel-height>2962</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr3/HIGHRES/image/jpeg/d8afb733595c50c55db9729ee38aa164/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr3/HIGHRES/image/jpeg/d8afb733595c50c55db9729ee38aa164/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>535046</xocs:filesize>
               <xocs:pixel-height>4297</xocs:pixel-height>
               <xocs:pixel-width>1386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr4/HIGHRES/image/jpeg/4f9ae9d488f5a75aac959865b02c3988/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr4/HIGHRES/image/jpeg/4f9ae9d488f5a75aac959865b02c3988/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>695335</xocs:filesize>
               <xocs:pixel-height>2546</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr5/HIGHRES/image/jpeg/76b0d2cebd0f75b804c66aec4a86c91a/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr5/HIGHRES/image/jpeg/76b0d2cebd0f75b804c66aec4a86c91a/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>760765</xocs:filesize>
               <xocs:pixel-height>2267</xocs:pixel-height>
               <xocs:pixel-width>3551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/gr6/HIGHRES/image/jpeg/10254ffba1f5f01771e25011d27fed43/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/gr6/HIGHRES/image/jpeg/10254ffba1f5f01771e25011d27fed43/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>143740</xocs:filesize>
               <xocs:pixel-height>1289</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/sc1/HIGHRES/image/jpeg/5602b7aa8c3afe3dbd4ab651dd627862/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/sc1/HIGHRES/image/jpeg/5602b7aa8c3afe3dbd4ab651dd627862/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>325706</xocs:filesize>
               <xocs:pixel-height>2521</xocs:pixel-height>
               <xocs:pixel-width>2567</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-mmc1.doc</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/mmc1/MAIN/application/msword/9fae3b1fddd05a2e35cb2e92f2d6f635/mmc1.doc</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/mmc1/MAIN/application/msword/9fae3b1fddd05a2e35cb2e92f2d6f635/mmc1.doc</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.doc</xocs:filename>
               <xocs:extension>doc</xocs:extension>
               <xocs:filesize>6957568</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-si1.gif</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/STRIPIN/image/gif/9b403c5acd048b6130c2c4396283ff01/si1.gif</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/STRIPIN/image/gif/9b403c5acd048b6130c2c4396283ff01/si1.gif</xocs:ucs-locator>
               <xocs:file-basename>si1</xocs:file-basename>
               <xocs:filename>si1.gif</xocs:filename>
               <xocs:extension>gif</xocs:extension>
               <xocs:filesize>1523</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>185</xocs:pixel-width>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523417300235-si2.gif</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523417300235/STRIPIN/image/gif/dbbeb11e8fe6f40ba90e619b73787d02/si2.gif</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523417300235/STRIPIN/image/gif/dbbeb11e8fe6f40ba90e619b73787d02/si2.gif</xocs:ucs-locator>
               <xocs:file-basename>si2</xocs:file-basename>
               <xocs:filename>si2.gif</xocs:filename>
               <xocs:extension>gif</xocs:extension>
               <xocs:filesize>8335</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>599</xocs:pixel-width>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>9166</aid>
            <ce:pii>S0223-5234(17)30023-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2017.01.015</ce:doi>
            <ce:copyright type="full-transfer" year="2017">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">The HPLC chromatogram of <ce:sup loc="pre">18</ce:sup>F labeled radiotracers and the corresponding <ce:sup loc="pre">19</ce:sup>F standards. The HPLC profile data were exported from the *.lcd files by Shimadzu LCSolution Software and were graphically interpreted and coordinate translated by Origin 8.0.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">The HPLC chromatogram of <ce:sup loc="pre">18</ce:sup>F labeled radiotracers in normal saline and murine plasma at 37 °C after 1 h and 2 h, respectively. The HPLC profile data were exported from the *.lcd files by Shimadzu LCSolution Software, and were graphically interpreted and coordinate translated by Origin 8.0.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Coronal Micro-PET/CT images of mice bearing S180 tumor at 30 min post-injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> (A), 60 min post-injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> (B), and 30 min post-injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> after treatment of PF-562,271 (a dose of 33 mg/kg, p.o.) at 1 h before the intravenous injection of radiotracer (blocking study) (C).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">(A) The chemical structure of NVP-TAE226; (B) View of the superimposed backbone atoms between the initial conformation (the receptor FAK in the drawing method “new cartoons” and blue color, while the ligand NVP-TAE226 in the drawing method “CPK” and red color) and the one extracted from the MD simulation with the cluster analysis (the receptor FAK in the drawing method “new cartoons” and orange color, while the ligand NVP-TAE226 in the drawing method“CPK”and yellow color) for the NVP-TAE226-FAK complex, which was graphically interpreted by VMD 1.9.1; (C) The root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation as a function of the simulation time, for the protein (red) and the ligand (blue) in the complex of the NVP-TAE226-FAK respectively, which were calculated with the <ce:italic>ptraj</ce:italic> module of Amber 10 and graphically interpreted by Origin 8.0. The MD simulation production phase was undertaken for 40 ns with a 2 ps time step, namely, 20000 snapshots in sum. The calculating time for the MD simulation for each compound was about one month on the basis of our current computer cluster condition. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">The root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation as a function of the simulation time, for the complex (red) and the ligand (blue) in the complexes respectively, which were calculated with the <ce:italic>ptraj</ce:italic> module of Amber 10 and graphically interpreted by Origin 8.0. The MD simulation production phase was undertaken for 40 ns with a 2 ps time step, namely, 20000 snapshots in sum. The calculating time for the MD simulation for each compound was about one month on the basis of our current computer cluster condition. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Comparison between the calculated and the experimental binding free energies estimated from IC<ce:inf loc="post">50</ce:inf>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Reagents and conditions: (a) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, <ce:sup loc="pre">i</ce:sup>PrOH:H2O = 1:1 (v/v), r. t.; (b) PTSA (<ce:italic>p</ce:italic>-Toluenesulfonic acid), 1,4-dioxane, reflux; (c) anhydrous KF, Kryptofix 2. 2. 2., anhydrous acetonitrile, 100 °C; (d) <ce:sup loc="pre">18</ce:sup>F<ce:sup loc="post">−</ce:sup>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, Kryptofix 2. 2. 2., anhydrous acetonitrile, 100 °C.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/sc1"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="tspara0010" view="all">
                     <ce:italic>In vitro</ce:italic> enzymatic activities of [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> against FAK compared to PF-562,271.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Table 1</ce:alt-text>
               <tgroup cols="2">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf>±SD (nM)<cross-ref refid="tbl1fna" id="crosref0380">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">276.2 ± 15.8</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">91.4 ± 6.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">425.7 ± 30.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PF-562,271</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.3 ± 0.3</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Mean of three determinations.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0015" view="all">
                     <ce:italic>In vitro</ce:italic> profile of [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> against a panel of five cancer-related kinases compared to NVP-TAE226.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Table 2</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf>±SD (nM) for [<sup loc="post">19</sup>F]2<cross-ref refid="tbl2fna" id="crosref0385">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf>±SD (nM) for NVP-TAE226<cross-ref refid="tbl2fna" id="crosref0390">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Reported IC<inf loc="post">50</inf> (nM) for NVP-TAE226</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PYK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2306.5 ± 274.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.7 ± 1.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.5 ± 2.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9419.3 ± 1039.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">868.9 ± 152.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">840 ± not shown</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IGF-1R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">29036.9 ± 3619.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">182.4 ± 40.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">140 ± 28.3</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">EGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3212.0 ± 423.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1829.1 ± 466.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1700 ± not shown</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PDGFRβ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">16477.4 ± 1385.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2321.0 ± 574.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2600 ± 1600</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Mean of three determinations.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl3" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="tspara0020" view="all">Biodistribution in mice bearing S180 tumor after intravenous injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>
                     <ce:cross-ref refid="tbl3fna" id="crosref0395">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref> (logP = 3.53 ± 0.05).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Table 3</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Organs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col6">Time (min)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">120</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.65 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.10 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.17 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.97 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.80 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Brain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.94 ± 0.80</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.97 ± 1.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.86 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.86 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.29 ± 0.25</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Heart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.02 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.24 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.21 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.09 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.25 ± 0.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.89 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.64 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.50 ± 0.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.45 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.56 ± 0.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Spleen</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.85 ± 1.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.39 ± 0.90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.37 ± 0.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.93 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.77 ± 0.45</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Lung</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">11.25 ± 0.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.71 ± 0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.49 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.85 ± 0.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.31 ± 0.60</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kidney</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">13.79 ± 0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.23 ± 1.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.13 ± 0.99</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.20 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.96 ± 0.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.68 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.72 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.74 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.14 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.59 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.78 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.06 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.24 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.58 ± 0.32</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Intestine<cross-ref refid="tbl3fnb" id="crosref0400">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.11 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.40 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.10 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.60 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.95 ± 0.04</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stomach<cross-ref refid="tbl3fnb" id="crosref0405">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.54 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.17 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.97 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.77 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.55 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.36 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.69 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.98 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.42 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.75 ± 0.17</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.29</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.97</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.45</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.56</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.69</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl3fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Expressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl3fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0025" view="all">Expressed as % injected dose per organ (%ID).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl4" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="tspara0025" view="all">Biodistribution in S180-tumor-bearing mice after intravenous injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>
                     <ce:cross-ref refid="tbl4fna" id="crosref0410">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref> (logP = 3.14 ± 0.03).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Table 4</ce:alt-text>
               <tgroup cols="7">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Organs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col6">Time (min)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">30 (blockade)<cross-ref refid="tbl4fnc" id="crosref0415">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">120</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.92 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.21 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.31 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.01 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.80 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.58 ± 0.31</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Brain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.84 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.62 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.74 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.68 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.31 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.38 ± 0.40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Heart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.90 ± 0.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.62 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.29 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.58 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.35 ± 0.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.87 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.45 ± 0.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.79 ± 0.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.43 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.80 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.29 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.31 ± 0.39</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Spleen</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.40 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.65 ± 0.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.59 ± 0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.97 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.55 ± 0.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Lung</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.71 ± 0.27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.67 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.15 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.18 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.86 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.41 ± 0.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kidney</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.30 ± 0.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.60 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.84 ± 0.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.71 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.02 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.25 ± 0.33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.86 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.73 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.85 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.10 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.86 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.82 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.16 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.10 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.21 ± 0.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.18 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.74 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Intestine<cross-ref refid="tbl4fnb" id="crosref0420">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.08 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.14 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.17 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.20 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.22 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.23 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stomach<cross-ref refid="tbl4fnb" id="crosref0425">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.43 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.58 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.57 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.50 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.33 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.47 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.27 ± 0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.47 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.80 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.54 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.79 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.02 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.83</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.19</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.50</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.65</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0030" view="all">Expressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0035" view="all">Expressed as % injected dose per organ (%ID).</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0040" view="all">Each animal received PF-562,271 (a dose of 33 mg/kg, p.o.) at 1 h before the intravenous radiotracer injection (blocking study).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl5" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0030" view="all">Biodistribution in S180-tumor-bearing mice after intravenous injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>
                     <ce:cross-ref refid="tbl5fna" id="crosref0430">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref> (logP = 2.92 ± 0.08).</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0075">Table 5</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Organs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col6">Time (min)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">120</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.34 ± 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.68 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.81 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.44 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.46 ± 0.24</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Brain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.00 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.46 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.45 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.23 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.47 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Heart</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.85 ± 0.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.69 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.28 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.22 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.08 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Liver</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.46 ± 1.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.03 ± 0.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.02 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.29 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.27 ± 0.04</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Spleen</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.49 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.51 ± 0.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.49 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.33 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.00 ± 0.05</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Lung</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.96 ± 0.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.70 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.21 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.82 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.36 ± 0.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kidney</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.68 ± 0.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.58 ± 0.39</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.28 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.35 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.31 ± 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.99 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.05 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.68 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.42 ± 0.07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.24 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.40 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.78 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.04 ± 0.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.36 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.40 ± 0.17</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Intestine<cross-ref refid="tbl5fnb" id="crosref0435">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.48 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.61 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.11 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.48 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.28 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Stomach<cross-ref refid="tbl5fnb" id="crosref0440">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.16 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.46 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.63 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.29 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.26 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.70 ± 0.38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.13 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.52 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.71 ± 0.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.77 ± 0.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Muscle</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.23</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Bone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor/Blood</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.49</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.90</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl5fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0045" view="all">Expressed as % injected dose per gram (%ID/g) unless otherwise indicated. Data are the average for five mice ± standard deviation.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl5fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0050" view="all">Expressed as % injected dose per organ (%ID).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl6" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0035" view="all">Results of free energy calculation by MM-PBSA and NMODE module of amber 10<ce:cross-ref refid="tbl6fna" id="crosref0445">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>, and the comparison between the calculated (δg<ce:inf loc="post">bind,,calc</ce:inf>)and the experimental binding free energies (δg<ce:inf loc="post">bind,,exp</ce:inf>) estimated from IC<ce:inf loc="post">50</ce:inf>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0080">Table 6</ce:alt-text>
               <tgroup cols="10">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <colspec colnum="8" colname="col8"/></colspec>
                  <colspec colnum="9" colname="col9"/></colspec>
                  <colspec colnum="10" colname="col10"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">complex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔE<inf loc="post">eletrostatic</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔE<inf loc="post">vdW</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔE<inf loc="post">gas</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔΔG<inf loc="post">PB</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔΔG<inf loc="post">SA</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔG<inf loc="post">MMPBSA</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TΔS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔG<inf loc="post">bind,calc</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔG<inf loc="post">bind,exp</inf>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>1</bold>-FAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−13.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−58.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−71.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">55.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−11.38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−27.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−18.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−9.08</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−8.94</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>2</bold>-FAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−12.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−57.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−70.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">56.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−11.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−25.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−16.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−9.44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−9.59</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">[<sup loc="post">19</sup>F]<bold>3</bold>-FAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−11.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−62.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−74.70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">58.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−12.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−28.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">−20.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−8.06</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>−8.68</bold>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl6fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0055" view="all">All energies are in kcal/mol.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523417300235-742bbe755e9f4c9e5702c0315fc2418c">
                  <ce:given-name>Yu</ce:given-name>
                  <ce:surname>Fang</ce:surname>
               </ce:author>
               <ce:author id="au2" author-id="S0223523417300235-17c7967129c89892600144019598b5ff">
                  <ce:given-name>Dawei</ce:given-name>
                  <ce:surname>Wang</ce:surname>
               </ce:author>
               <ce:author id="au3" author-id="S0223523417300235-77c7d406c2712fe77bd628b8f4e3578f">
                  <ce:given-name>Xingyu</ce:given-name>
                  <ce:surname>Xu</ce:surname>
               </ce:author>
               <ce:author id="au4" author-id="S0223523417300235-440d68386401b3a1af90f8b17d42cd78">
                  <ce:given-name>Jianping</ce:given-name>
                  <ce:surname>Liu</ce:surname>
               </ce:author>
               <ce:author id="au5" author-id="S0223523417300235-00138fda98d477661a9008445e230437">
                  <ce:given-name>Aiqin</ce:given-name>
                  <ce:surname>Wu</ce:surname>
               </ce:author>
               <ce:author id="au6" author-id="S0223523417300235-69b18c49c75f343a6875fbb93d2960b9">
                  <ce:given-name>Xiang</ce:given-name>
                  <ce:surname>Li</ce:surname>
               </ce:author>
               <ce:author id="au7" author-id="S0223523417300235-66f24bc27503a83bc54771930f2143df">
                  <ce:given-name>Qianqian</ce:given-name>
                  <ce:surname>Xue</ce:surname>
               </ce:author>
               <ce:author id="au8" author-id="S0223523417300235-01a5c1d351e7573471a051f7b7fb0661">
                  <ce:given-name>Huan</ce:given-name>
                  <ce:surname>Wang</ce:surname>
               </ce:author>
               <ce:author id="au9" author-id="S0223523417300235-0b4cfd4fbaf582be8787b7f76023f426">
                  <ce:given-name>Hang</ce:given-name>
                  <ce:surname>Wang</ce:surname>
               </ce:author>
               <ce:author id="au10" author-id="S0223523417300235-d6368f03c39b1ce425055508f93c64b3">
                  <ce:given-name>Huabei</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref refid="cor1" id="crosref0010">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:textfn>Key Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, No. 19 Xinjiekouwai Street, Haidian District, Beijing 100875, People's Republic of China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Key Laboratory of Radiopharmaceuticals of Ministry of Education</sa:organization>
                     <sa:organization>College of Chemistry</sa:organization>
                     <sa:organization>Beijing Normal University</sa:organization>
                     <sa:address-line>No. 19 Xinjiekouwai Street</sa:address-line>
                     <sa:address-line>Haidian District</sa:address-line>
                     <sa:city>Beijing</sa:city>
                     <sa:postal-code>100875</sa:postal-code>
                     <sa:country>People's Republic of China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="8" month="10" year="2016"/></ce:date-received>
            <ce:date-revised day="8" month="1" year="2017"/></ce:date-revised>
            <ce:date-accepted day="10" month="1" year="2017"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Focal adhesion kinase (FAK) is considered as an attractive target for oncology. A series of F-18 labeled 5-bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxyphenyl)pyrimidine-2,4-diamine derivatives were prepared and evaluated as the FAK targeted radiotracers for the early diagnoses of tumor. For the study of the FAK targeted drug molecules, this was the first attempt to develop the tumor diagnostic imaging agents on the radiopharmaceutical level. They inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> in the range of 91.4–425.7 nM, and among which the result of the [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> was relatively good and had a modest IC<ce:inf loc="post">50</ce:inf> of 91.4 nM. The [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> was also profiled <ce:italic>in vitro</ce:italic> against some other kinds of cancer-related kinases (including two kinds of non-receptor tyrosine kinase: PYK2 and JAK2, and three kinds of receptor tyrosine kinase: IGF-1R, EGFR and PDGFRβ). It displayed 25.2 folds selectivity against PYK2, 35.1 folds selectivity against EGFR, and more than 100 folds selectivity against IGF-1R, JAK2 and PDGFRβ. For the biodistribution in S180 bearing mice, the corresponding [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> were also relatively good, with modest tumor uptake of 5.47 ± 0.19 and 5.80 ± 0.06 %ID/g at 15 and 30 min post-injection, respectively. Furthermore, its tumor/muscle, tumor/bone and tumor/blood ratio at 15 min post-injection were 3.16, 2.53 and 4.52, respectively. And its tumor/muscle, tumor/bone and tumor/blood ratio at 30 min post-injection were 3.14, 2.76 and 4.43, respectively. In addition, coronal micro-PET/CT images of a mouse bearing S180 tumor clearly confirmed that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> could be accumulated in tumor, especially at 30 min post-injection. Besides, for the [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, both the biodistribution data and the micro-PET/CT imaging study showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> value of 1.5 nM) at 1 h before the injection of radiotracer. In combination with the above kinase profiling assay, it could be indicated that the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor of the mouse model was due to FAK expression, and that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> might be a kind of selectively FAK targeted tumor imaging agents. What's more, the results of the MD (molecular dynamics) simulations were in agreement with the changing trends of the interaction between the different F-19 standards and the FAK (expressed as the <ce:italic>in vitro</ce:italic> inhibitory abilities of enzymatic activities of FAK in this article), which was also in agreement with and had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>F-18 labeled</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Focal adhesion kinase (FAK)</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Radiotracers</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Tumor imaging</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Molecular dynamics (MD) simulation</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">As a 125 kDa non-receptor and cytoplasmic tyrosine kinase and scaffold protein highly conserved and localized in focal adhesions which was discovered 24 years ago by several different groups <ce:cross-refs refid="bib1 bib2" id="crosrefs0010">[1,2]</ce:cross-refs>, Focal Adhesion Kinase (FAK) modulates cell adhesion, migration, proliferation, survival, apoptosis and so on <ce:cross-refs refid="bib3 bib4 bib5 bib6 bib7 bib8" id="crosrefs0015">[3–8]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0030" view="all">A large amount of evidence has suggested that FAK signaling pathways can stimulate tumor development, progression and metastasis through their regulation both cancer cells and their microenvironments including cell migration, invasion, extracellular matrix (ECM), epithelial to mesenchymal transition, and angiogenesis <ce:cross-refs refid="bib9 bib10 bib11 bib12 bib13 bib14 bib15 bib16 bib17 bib18 bib19 bib20 bib21 bib22 bib23 bib24 bib25 bib26 bib27" id="crosrefs0020">[9–27]</ce:cross-refs>. It is known to all that in most kinds of tumor cells, FAK is overexpressed or highly expressed <ce:cross-refs refid="bib25 bib26 bib27" id="crosrefs0025">[25–27]</ce:cross-refs>. What's more, FAK overexpression or high expression is a prognostic predictor in a wide variety of cancers <ce:cross-refs refid="bib25 bib26 bib27" id="crosrefs0030">[25–27]</ce:cross-refs>, involving hepatocellular carcinoma <ce:cross-refs refid="bib28 bib29 bib30" id="crosrefs0035">[28–30]</ce:cross-refs>, invasive breast carcinoma <ce:cross-refs refid="bib31 bib32 bib33" id="crosrefs0040">[31–33]</ce:cross-refs>, intestinal-type gastric carcinoma <ce:cross-ref refid="bib34" id="crosref0015">[34]</ce:cross-ref>, endometric cancer <ce:cross-ref refid="bib35" id="crosref0020">[35]</ce:cross-ref>, acute myeloid leukemia <ce:cross-refs refid="bib36 bib37" id="crosrefs0045">[36,37]</ce:cross-refs>, anaplastic astrocytoma tumor <ce:cross-refs refid="bib38 bib39" id="crosrefs0050">[38,39]</ce:cross-refs>, sarcoma <ce:cross-ref refid="bib32" id="crosref0025">[32]</ce:cross-ref>(such as osteosarcoma) <ce:cross-ref refid="bib40" id="crosref0030">[40]</ce:cross-ref>, ovarian carcinoma <ce:cross-ref refid="bib41" id="crosref0035">[41]</ce:cross-ref>, neuroblastoma <ce:cross-ref refid="bib42" id="crosref0040">[42]</ce:cross-ref>, thyroid cancer <ce:cross-ref refid="bib43" id="crosref0045">[43]</ce:cross-ref>, prostate cancer <ce:cross-ref refid="bib44" id="crosref0050">[44]</ce:cross-ref>, head and neck squamous cell carcinoma <ce:cross-ref refid="bib45" id="crosref0055">[45]</ce:cross-ref> and so on. (However, some individual and conflicting cases still cause our attention <ce:cross-refs refid="bib25 bib26 bib27" id="crosrefs0055">[25–27]</ce:cross-refs>. On one side, some data show no prognostic value of FAK high expression or overexpression for some kind of cancers. On the other side, increased expression of FAK has been shown in some studies to be correlated with better outcome in some kinds of cancer patients.)</ce:para>
                  <ce:para id="p0035" view="all">Consequently, FAK inhibition is considered as an effective antineoplastic strategy by inducing apoptosis and sensitizing tumor cells to chemotherapy anyway <ce:cross-ref refid="bib13" id="crosref0060">[13]</ce:cross-ref>. A lot of FAK inhibitors have been developed, some even in clinical phase II trial. On the whole, small molecular FAK inhibitors can be classified into two kinds <ce:cross-ref refid="bib26" id="crosref0065">[26]</ce:cross-ref>: (a) Kinase-dependent functions of FAK targeted inhibitors. This category may be subdivided into two distinct classifications. The first subclass of inhibitors bind to the ATP-binding site and compete directly with ATP (Such as PF-573,228 <ce:cross-ref refid="bib46" id="crosref0070">[46]</ce:cross-ref>, PF-562,271 <ce:cross-ref refid="bib11" id="crosref0075">[11]</ce:cross-ref>, PF-431,396 <ce:cross-ref refid="bib47" id="crosref0080">[47]</ce:cross-ref>, PF-04554878 <ce:cross-ref refid="bib48" id="crosref0085">[48]</ce:cross-ref> developed by Pfizer Inc.; 7H-pyrrolo [2,3-d]pyrimidines <ce:cross-ref refid="bib49" id="crosref0090">[49]</ce:cross-ref>, NVP-TAC544 <ce:cross-ref refid="bib50" id="crosref0095">[50]</ce:cross-ref>, NVP-TAE-226 <ce:cross-ref refid="bib10" id="crosref0100">[10]</ce:cross-ref> developed by Novartis AG; 1H-Pyrrolo [2,3-b]- and 3H-Imidazolo [4,5-b]-Pyridines <ce:cross-ref refid="bib13" id="crosref0105">[13]</ce:cross-ref> developed by Merck KGaA; PND-1186 <ce:cross-ref refid="bib51" id="crosref0110">[51]</ce:cross-ref> developed by Poniard; Pyrrolo [2,1-f] [1,2,4]triazines <ce:cross-ref refid="bib52" id="crosref0115">[52]</ce:cross-ref> developed by Cephalon, Inc.; Diarylamino-1,3,5-triazines <ce:cross-ref refid="bib12" id="crosref0120">[12]</ce:cross-ref> and Imidazo [1,2-a] [1,3,5]triazines <ce:cross-ref refid="bib9" id="crosref0125">[9]</ce:cross-ref> developed by Université Paris Descartes; VS-6063 <ce:cross-ref refid="bib53" id="crosref0130">[53]</ce:cross-ref>, VS-4718(#<ce:inter-ref xlink:href="ctgov:NCT01849744" id="intref0010" xlink:type="simple">NCT01849744</ce:inter-ref>), VS-5095 <ce:cross-ref refid="bib54" id="crosref0135">[54]</ce:cross-ref> from Verastem; GSK-2256098 <ce:cross-ref refid="bib55" id="crosref0140">[55]</ce:cross-ref> developed by Glaxo Smith Kline). The second subclass involve inhibitors that bind to an allosteric site within the FAK kinase domain distant from the ATP-binding site and thus do not compete directly with ATP but still block kinase activity (For instance, Pyrazolo [4,3-c] [1,2]benzothiazines <ce:cross-ref refid="bib56" id="crosref0145">[56]</ce:cross-ref> that targeted a novel allosteric site within the C-lobe of the kinase domain, which induces disruption of ATP pocket formation leading to the inhibition of kinase activity; Y15 <ce:cross-ref refid="bib57" id="crosref0150">[57]</ce:cross-ref> targeting Y397 site anddecreasing the Y418-phosphorylation of down-stream Src in colon cancer cells.). (b) Inhibitors targeting the scaffolding function of FAK (For example, (CFAK) C4 <ce:cross-ref refid="bib58" id="crosref0155">[58]</ce:cross-ref> which inhibits the binding of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) to FAK; INT2-31 <ce:cross-ref refid="bib59" id="crosref0160">[59]</ce:cross-ref> inhibiting the interaction of c-Met and IGF-1R with FAK; M13 <ce:cross-ref refid="bib60" id="crosref0165">[60]</ce:cross-ref> disrupting the FAK and Mdm-2 interaction; R2 <ce:cross-ref refid="bib61" id="crosref0170">[61]</ce:cross-ref> disrupting the FAK and p53 interaction).</ce:para>
                  <ce:para id="p0040" view="all">To the best of our knowledge, however, people concentrated on the research of FAK small molecule inhibitors for the tumor therapy at the level of the generic pharmaceuticals level, while no previous reports were committed to the development of FAK targeted radiotracers for tumor radiotracers at the level of radiopharmaceutical. Therefore, in this study, the first attempt were made to develop a series of F-18 labeled 5-bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxyphenyl)-pyrimidine-2,4-diamine derivatives as the FAK targeted radiotracers for the early diagnoses of tumor, with organic and radiosyntheses, <ce:italic>in vitro</ce:italic> stability test, <ce:italic>in vitro</ce:italic> FAK inhibitory assay, <ce:italic>in vitro</ce:italic> kinase selectivity profiling assay for the compound which have relative good result of <ce:italic>in vitro</ce:italic> FAK inhibitory assay, <ce:italic>in vivo</ce:italic> biodistribution evaluation and micro-PET/CT imaging study in S180 bearing mice (including blocking study). In addition, we performed the MD (molecular dynamics) simulations to gain better understanding of the changing trends of the interaction between the different F-19 standards and the FAK, which had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0045" view="all">The synthesis of the tosylate precursors <ce:bold>8a-8c</ce:bold> and the fluoro-pegylated 5-bromopyrimidine derivatives [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1-</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> are outlined in <ce:cross-ref refid="sch1" id="crosref0175">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>. The starting material 5-bromo-2,4-dichloropyrimidine <ce:bold>4</ce:bold> reacted with the 4-methoxyphenyl amine <ce:bold>5</ce:bold> to yield the 5-bromo-2-chloro-<ce:italic>N</ce:italic>-(4-methoxyphenyl)pyrimidin-4-amine <ce:bold>6</ce:bold> under K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>. Then, in presence of <ce:italic>p</ce:italic>-toluenesulfonic acid (PTSA), the compound <ce:bold>12</ce:bold> were treated with the different substituted aryl amines <ce:bold>7a-7c</ce:bold> above to obtain the desired tosylate precursors <ce:bold>8a-8c</ce:bold>. The F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1-</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> of the corresponding radiotracers [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1-</ce:bold>[<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold> in this work was obtained by the stirring of the tosylate precursors <ce:bold>8a-8c</ce:bold> with anhydrous KF and Kryptofix 2. 2. 2 using the dry acetonitrile as the solvent in the digestion high-pressure tank at 100 °C for just 15 min.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Radiolabeling</ce:section-title>
                     <ce:para id="p0050" view="all">In this work, we treated tosylate precursors <ce:bold>8a, 8b,</ce:bold> and <ce:bold>8c</ce:bold> with [<ce:sup loc="post">18</ce:sup>F]fluoride/potassium carbonate and Kryptofix 2. 2. 2. in anhydrous acetonitrile using a digestion high-pressure tank at 100 °C for 15 min (<ce:cross-ref refid="sch1" id="crosref0180">Scheme 1</ce:cross-ref>), respectively, in order to make the desired <ce:sup loc="pre">18</ce:sup>F-labeled tracers [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1,</ce:bold> [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, with radiochemical yields of 13%, 9%, and 7%, respectively (decay not corrected). The radiochemical purity of these radiotracers was greater than 98% after purification by high performance liquid chromatography (HPLC). The identity of <ce:sup loc="pre">18</ce:sup>F-labeled tracers was verified by a comparison of the retention time with those of the corresponding nonradioactive F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1,</ce:bold> [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> via co-injection. The retention time of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1,</ce:bold> [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold> were 13.632 min, 14.463 min and 14.261 min, respectively, which matched well with the corresponding F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold> (13.775 min), [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> (14.112 min) and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> (13.900 min) within admissible error, respectively (<ce:cross-ref refid="fig1" id="crosref0185">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>). Specific activity, estimated by comparing the UV peak intensity of purified <ce:sup loc="pre">18</ce:sup>F labeled compounds with reference nonradioactive compounds, the specific activity ranged from 42 to 50 GBq/μmol at the end of synthesis.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">In vitro stability study</ce:section-title>
                     <ce:para id="p0055" view="all">The radio-HPLC showed that all the three radiotracers were stable in both normal saline and murine plasma at 37 °C after 1 h and 2 h. <ce:cross-ref refid="fig2" id="crosref0190">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor> illustrated the <ce:italic>in vitro</ce:italic> stability of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> for example:</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Biological activity</ce:section-title>
                     <ce:section id="sec2.4.1" view="all">
                        <ce:label>2.4.1</ce:label>
                        <ce:section-title id="sectitle0060">FAK inhibitory assay of the F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold>, and kinase selectivity profile of the F-19 standard [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0060" view="all">All compounds were evaluated for their ability to inhibit FAK kinase activity using an HTRF<ce:sup loc="post">®</ce:sup> (Homogeneous Time-Resolved Fluorescence Methodologies) based kinase assay described in Section <ce:cross-ref refid="sec4.6" id="crosref0195">4.6</ce:cross-ref>. One reported inhibitor of FAK, PF-562,271, developed by Pfitzer Inc., was included to validate the FAK inhibitory assay conditions. Under the experimental conditions, PF-562,271 inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> value of 4.3 nM (<ce:cross-ref refid="tbl1" id="crosref0200">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor>), which was similar to previously reported data (1.5 nM) <ce:cross-ref refid="bib11" id="crosref0205">[11]</ce:cross-ref>.</ce:para>
                        <ce:para id="p0065" view="all">As shown in <ce:cross-ref refid="tbl1" id="crosref0210">Table 1</ce:cross-ref>, the interaction between the F-19 standards in this work ([<ce:sup loc="post">19</ce:sup>F]<ce:bold>1-</ce:bold> [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold>) and the FAK, was mainly affected by the length of the FPEG chain. When the FPEG chain on the F-19 standards was lengthened from n = 1 to n = 2, the FAK inhibitory potency improved by 3-fold. The result of the [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> were relatively good and had a modest IC<ce:inf loc="post">50</ce:inf> of 91.4 nM. So we continued to lengthen the FPEG chain. Unfortunately, contrary to our expectation, the addition of the FPEG chain from n = 2 to n = 3, resulted in the incredible 4.7-fold reduction of interaction between the F-19 standards and the FAK.</ce:para>
                        <ce:para id="p0070" view="all">We further profiled the relatively best F-19 standard [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>, <ce:italic>in vitro</ce:italic> against a panel of five kinds of cancer-related kinases (including two kinds of non-receptor tyrosine kinase and three kinds of receptor tyrosine kinase), also using an HTRF<ce:sup loc="post">®</ce:sup> based kinase assay described in Section <ce:cross-ref refid="sec4.6" id="crosref0215">4.6</ce:cross-ref> (in view of the availability of the types of kinases for us, and the financial ability of our research group) (PYK2, JAK2, IGF-1R, EGFR and PDGFRβ: 1. PYK2, of which full name is Proline-rich tyrosine kinase 2, is a non-receptor tyrosine kinase, belonging to the same FAK family with that of FAK; 2. JAK2, of which full name is Janus kinase 2, is a non-receptor tyrosine kinase, and a member of the JAK family; 3. IGF-1R, namely Insulin-like growth factor-1 receptor, is a receptor tyrosine kinase; 4. EGFR, namely Epidermal growth factor receptor or ErbB-1 or HER1 in humans, is a non-receptor tyrosine kinase, and a member of the EGF receptor family (also called ErbB family); 5. PDGFRβ, with full name of Platelet-derived growth factor receptor beta, is a receptor tyrosine kinase, and a member of the PDGF receptor family). One reported inhibitor of FAK, NVP-TAE226, developed by Novartis International AG, was included to validate the kinase selectivity profiling assay conditions. Under the experimental conditions, the IC<ce:inf loc="post">50</ce:inf> values with which NVP-TAE226 inhibited the activity of the above five kinds of kinases, were also similar to previously reported data <ce:cross-ref refid="bib62" id="crosref0220">[62]</ce:cross-ref>.</ce:para>
                        <ce:para id="p0075" view="all">The results in <ce:cross-ref refid="tbl2" id="crosref0225">Table 2</ce:cross-ref>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor> revealed that the F-19 standard [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> displayed an good selectivity profile against the tested kinases. It displayed 25.2 folds selectivity against PYK2, 35.1 folds selectivity against EGFR, and more than 100 folds selectivity against IGF-1R, JAK2 and PDGFRβ.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.4.2" view="all">
                        <ce:label>2.4.2</ce:label>
                        <ce:section-title id="sectitle0065">Biodistribution of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1,</ce:bold> [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold> in mice bearing S180 tumor</ce:section-title>
                        <ce:para id="p0080" view="all">In general, as shown in <ce:cross-ref refid="tbl3" id="crosref0230">Table 3</ce:cross-ref>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>, <ce:cross-ref refid="tbl4" id="crosref0235">Table 4</ce:cross-ref>
                           <ce:float-anchor refid="tbl4"/></ce:float-anchor> and <ce:cross-ref refid="tbl5" id="crosref0240">Table 5</ce:cross-ref>
                           <ce:float-anchor refid="tbl5"/></ce:float-anchor>, for all of the three F-18 labeled compounds in this work, their uptake in tumor were at their respective high levels at 15 min post-injection (4.69 ± 0.16, 5.47 ± 0.19 and 4.13 ± 0.08 %ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, respectively), and stayed at similarly high levels at 30 min post-injection (4.98 ± 0.09, 5.80 ± 0.06 and 4.52 ± 0.11%ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, respectively). The value reached the peak at 30 min post-injection (4.98 ± 0.09, 5.80 ± 0.06, 4.52 ± 0.11 %ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, respectively). Then, the uptake of the three radiotracers decreased at 60 min post-injection and 120 min post-injection. But on the other hand, after 120 min post-injection, the radioactivity was still more than half of the peak value. They were 3.75 ± 0.17 %ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, 3.79 ± 0.23 %ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> and 2.77 ± 0.16 %ID/g for [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, respectively, indicating that all the three tracers remained in tumor for a relatively long time.</ce:para>
                        <ce:para id="p0085" view="all">The length of the FPEG chain had a great influence, not only on the interaction between the F-19 standards in this work ([<ce:sup loc="post">19</ce:sup>F]<ce:bold>1-</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold>) and the FAK at the molecular level, but also on the biodistribution of the corresponding F-18 labeled radiotracers ([<ce:sup loc="post">18</ce:sup>F]<ce:bold>1-</ce:bold>[<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>) in mice bearing S180 tumor models at the organ level. With the addition of the FPEG chain from n = 1 to n = 2, both the uptake of the radiotracers in tumor and some of their target/non-target ratio (tumor/bone, tumor/muscle and tumor/blood ratio, e.g.) increased. It was most likely to be the common result of two factors: (1) When the FPEG chain lengthened from n = 1 to n = 2, the FAK inhibitory activity of the corresponding F-19 standards raised, indicating a strengthened interaction between the F-19 standards and the FAK. And since the FAK was overexpressed or high-expressed in most kinds of tumor cells (including S180 as murine sarcoma cell line), so the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor and some of its target/non-target ratios (tumor/bone, tumor/muscle and tumor/blood ratio, e.g.) was higher than those of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>; (2) The logP of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> (3.14 ± 0.03) was lower than that of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold> (3.53 ± 0.05), probably also enhance the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor. Unfortunately, though the logP of the F-18 labeled tracer continued to become lower when the FPEG chain lengthened from n = 2 to n = 3, the uptake of [<ce:sup loc="post">18</ce:sup>F] <ce:bold>3</ce:bold> in tumor and some of its target/non-target ratio were reduced dramatically (even lower than those of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>), with the incredible weakening of interaction between the F-19 standards and the FAK.</ce:para>
                        <ce:para id="p0090" view="all">For the [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, significantly reduced uptake (∼82%) of the radiotracer in the tumor tissue (1.02 ± 0.35 %ID/g at 30 min post-injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>) was observed in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> value of 1.5 nM) at 1 h before the injection of radiotracer (blocking assay). Thus, our biodistribution data, in combination with the results of the above kinase profiling assay, indicated that the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor of the mouse model was due to FAK expression, and that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> might be a kind of selectively FAK-targeted tumor imaging agents.</ce:para>
                        <ce:para id="p0095" view="all">From the analysis presented above, we could see that the trends of the uptake of the F-18 labeled tracers in tumor and some of theirs target/non-target ratios (tumor/bone, tumor/muscle and tumor/blood ratio, e.g.) in this study were mainly affected by and in agreement with the trends of the interaction between the corresponding F-19 standards and the FAK (expressed as the <ce:italic>in vitro</ce:italic> inhibitory abilities of enzymatic activities of FAK in this article). Therefore, for the future design of the FAK-targeted F-18 labeled tumor radiotracers, the interaction between the with the corresponding F-19 standards and the FAK should be further increased and the logP should be properly lowered, in order to enhance the uptake of the F-18 labeled tracer in tumor and its target/non-target ratios.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.4.3" view="all">
                        <ce:label>2.4.3</ce:label>
                        <ce:section-title id="sectitle0070">
                           <ce:italic>Micro-PET/CT imaging studies of [</ce:italic>
                           <ce:sup loc="post">
                              <ce:italic>18</ce:italic>
                           </ce:sup>
                           <ce:italic>F]</ce:italic>
                           <ce:bold>2</ce:bold> 
                           <ce:italic>in mice bearing S180 tumor</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0100" view="all">We selected the [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, which showed relatively good biodistribution results, to perform the small animal PET/CT imaging studies in the mouse bearing S180 tumor. The mouse was injected intravenously with approximately 3.7 MBq of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in normal saline and anesthetized with 1.5% isoflurane for imaging. Coronal micro-PET/CT images of a mouse bearing S180 tumor at 30 and 60 min after tail vein injection of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> were shown in <ce:cross-ref refid="fig3" id="crosref0245">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>A and <ce:cross-ref refid="fig3" id="crosref0250">Fig. 3</ce:cross-ref>B, respectively. In agreement with the above biodistribution results, relatively high tracer uptake in tumor (pointed to by the arrowhead) in the right front flank was observed at 30 min post-injection, while no accumulation in the left front flank was found. At 60 min post-injection, the tracer uptake in tumor (pointed to by the arrowhead) in the right front flank was slower, but it was still obvious. The imaging results clearly confirmed that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> could be accumulated in tumor, especially at 30 min post-injection. In addition, both at 30 min post-injection and at 60 min post-injection, the activity in bladder was also obvious, which was due to the metabolism in kidney.</ce:para>
                        <ce:para id="p0105" view="all">What's more, <ce:cross-ref refid="fig3" id="crosref0255">Fig. 3</ce:cross-ref>C (blocking study) showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> value of 1.5 nM) at 1 h before the injection of radiotracer. Therefore, the micro-PET/CT imaging study, in combination with the results of the above kinase profiling assay, also indicated that the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor of the mouse model was due to FAK expression, and that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> might be a kind of selectively FAK targeted tumor imaging agents.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0075">Molecular dynamics (MD) simulations</ce:section-title>
                     <ce:para id="p0110" view="all">In an effort to gain better understanding of the changing trends of the interaction between the different F-19 standards and the FAK, and the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios in theory, we proceeded to do molecular dynamics (MD) simulations, since the MD simulations were undertaken in the state close to natural conditions with treating the complexes (consisted of ligands such as the F-19 standards in this work and receptors such as FAK in this study) in aqueous solution, while the solvent effect on the potential conformational changes of the complexes were not fully taken into account in the mere docking analysis.</ce:para>
                     <ce:para id="p0115" view="all">First, to prove the rationality of the MD simulations and the validity of the molecular conformation that was used as the initial conformation for the MD simulations, the NVP-TAE226 (the ligand that forming the complex with FAK (PDB ID of the crystal structures determined by the X-ray single-crystal diffraction: 2JKK) and that was selected as the molecular template for sketching the structure of the F-19 standards in this work) (<ce:cross-ref refid="fig4" id="crosref0260">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>A) was served as starting structures for MD simulation using Amber10. Whether for the complex or for the ligand, it could be noticed that from <ce:cross-ref refid="fig4" id="crosref0265">Fig. 4</ce:cross-ref>B that, there were no significant differences between the conformations extracted from MD simulations and the ones in the crystal structures determined by the X-ray single-crystal diffraction. <ce:cross-ref refid="fig4" id="crosref0270">Fig. 4</ce:cross-ref>C also showed the root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation are less than 2 Å. As suggested above, both the conformation of the whole complex and that of the ligand were still stable during the MD simulation.</ce:para>
                     <ce:para id="p0120" view="all">Next, the 40ns MD simulations were carried out for all the three F-19 standards in this study, respectively (<ce:cross-ref refid="fig5" id="crosref0275">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>). Most of the RMSD values between the initial conformation and the one during the MD simulation after reaching a state of equilibrium, were less than 2.0 Å. What's more, the weaker the FAK inhibitory activity the F-19 standard had, the weaker the interaction between the F-19 standard and the FAK, the longer the time the complex system would spend to reach the equilibrium state.</ce:para>
                     <ce:para id="p0125" view="all">The components of molecular mechanics and solvation energies are listed in <ce:cross-ref refid="tbl6" id="crosref0280">Table 6</ce:cross-ref>
                        <ce:float-anchor refid="tbl6"/></ce:float-anchor>. For the electrostatic energy (ΔE<ce:inf loc="post">eletrostatic</ce:inf>+ΔΔG<ce:inf loc="post">PB</ce:inf>), the mean value was 44.2 kcal/mol with an root-mean-square deviation of 2.4 kcal/mol. The mean value of van der Waals and hydrophobic interaction energies (ΔE<ce:inf loc="post">vdW</ce:inf>+ΔΔG<ce:inf loc="post">SA</ce:inf>), was −71.5 kcal/mol with an root-mean-square deviation of 3.3 kcal/mol. The entropy (TΔS) had a root-mean-square deviation of 2.0 kcal/mol with a mean value of −18.4 kcal/mol. The average unsigned error between the experimental and the calculated energy was 0.30 kcal/mol and the root-mean-square deviation was 0.27 kcal/mol. It was indicated in <ce:cross-ref refid="fig6" id="crosref0285">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor> that the calculated free energies reproduced the experimental ones relatively well and the rank order of calculated free energies was generally in agreement with that of the experimental ones.</ce:para>
                     <ce:para id="p0130" view="all">Overall, the results of the MD simulations were in consistent with the changing trends of the interaction between the different F-19 standards and the FAK, which had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0080">Conclusion</ce:section-title>
                  <ce:para id="p0135" view="all">A series of 5-bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-fluoro-pegylated (FPEG))-3,5-dimethoxyphenyl)-N<ce:sup loc="post">4</ce:sup>- (4-methoxyphenyl)-pyrimidine-2,4-diamine derivatives were prepared through efficient organic and radiosyntheses, and evaluated as the FAK-targeted radiotracers for the early diagnoses of tumor. For the study of the FAK-targeted drug molecules, this was the first attempt to develop the tumor diagnostic imaging agents on the radiopharmaceutical level, since all of the studies before this were just focused on the development and evaluation of FAK small molecule inhibitors for the tumor therapy at the level of generic pharmaceuticals.</ce:para>
                  <ce:para id="p0140" view="all">All the F-18 labeled compounds in this work displayed high <ce:italic>in vitro</ce:italic> stability in normal saline solution and murine plasma. In the kinase inhibitory assays, the corresponding F-19 standards displayed abilities to inhibit the activity of FAK with IC<ce:inf loc="post">50</ce:inf> values that varied from 91.4 to 425.7 nM, and among which the result of the [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> with an FPEG chain of medium-length (n = 2) were relatively good and had a modest IC<ce:inf loc="post">50</ce:inf> of 91.4 nM. The [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> was also profiled <ce:italic>in vitro</ce:italic> against some other kinds of cancer-related kinases (including two kinds of non-receptor tyrosine kinase: PYK2 and JAK2, and three kinds of receptor tyrosine kinase: IGF-1R, EGFR and PDGFRβ). It displayed 25.2 folds selectivity against PYK2, 35.1 folds selectivity against EGFR, and more than 100 folds selectivity against IGF-1R, JAK2 and PDGFRβ. For the biodistribution in mice bearing S180 tumor, the corresponding [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> were also relatively good among the three F-18 labeled compounds in this study, with modest tumor uptake of 5.47 ± 0.19 %ID/g and 5.80 ± 0.06 %ID/g at 15 and 30 min post-injection, respectively. Furthermore, its tumor/muscle, tumor/bone and tumor/blood ratio at 15 min post-injection were 3.16, 2.53 and 4.52, respectively. And its tumor/muscle, tumor/bone and tumor/blood ratio at 30 min post-injection were 3.14, 2.76 and 4.43, respectively. In addition, coronal micro-PET/CT images of a mouse bearing S180 tumor clearly confirmed that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> could be accumulated in tumor, especially at 30 min post-injection. Besides, for the [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, both the biodistribution data and the micro-PET/CT imaging study showed significantly reduced uptake of the radiotracer in the tumor tissue at 30 min post-injection in mice that received PF-562,271 (one of the reported best selective FAK inhibitor which was developed by Pfitzer Inc. and inhibited the activity of FAK with IC<ce:inf loc="post">50</ce:inf> value of 1.5 nM) at 1 h before the injection of radiotracer. In combination with the above kinase profiling assay, it could be indicated that the uptake of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in tumor of the mouse model was due to FAK expression, and that [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> might be a kind of selectively FAK-targeted tumor imaging agents.</ce:para>
                  <ce:para id="p0145" view="all">What's more, the results of the MD (molecular dynamics) simulations were in consistent with the changing trends of the interaction between the different F-19 standards and the FAK (expressed as the <ce:italic>in vitro</ce:italic> inhibitory abilities of enzymatic activities of FAK in this article), which was also in agreement with and had great effect on the changing trends of the uptake of the corresponding F-18 labeled tracers in tumor and some of theirs target/non-target ratios.</ce:para>
                  <ce:para id="p0150" view="all">Further studies on [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> are under way. Furthermore, in the future design of the F-18 labeled tumor radiotracers targeting FAK, the interaction between the corresponding F-19 standards and the FAK should be further increased and the logP should be further properly lowered, in order to enhance the uptake of the F-18 labeled tracer in tumor and its target/non-target ratios, leading to develop FAK targeted and F-18 labeled tumor radiotracers which are more suitable for PET/CT scan.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0085">Experiments</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0090">Materials and measurements</ce:section-title>
                     <ce:para id="p0155" view="all">All chemicals and reagents used in this study were obtained from commercial sources and were of analytical grade. <ce:sup loc="pre">1</ce:sup>H NMR spectra were measured at 400 MHz on a BRUKER AVANCE<ce:sup loc="post">®</ce:sup> III HD 400 Spectrometer in CDCl<ce:inf loc="post">3</ce:inf> with chemical shift (<ce:italic>δ</ce:italic>) given in parts per million (ppm) relative to TMS as internal standard and recorded at 25 °C. <ce:sup loc="pre">13</ce:sup>C NMR spectra were measured at 100 MHz on a JEOL<ce:sup loc="post">®</ce:sup> 400 YH Spectrometer in DMSO-<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> with chemical shift (<ce:italic>δ</ce:italic>) given in parts per million (ppm) relative to TMS as internal standard and recorded at 25 °C. MS (ESI) spectra was determined by using a Waters Quattro Micro<ce:sup loc="post">®</ce:sup> Quadrupole Mass Spectrometer or a Shimidzu<ce:sup loc="post">®</ce:sup> LCMS-2010 Quadrupole Mass Spectrometer. Silica plates (60 GF<ce:inf loc="post">254</ce:inf>) were used for thin layer chromatography (TLC) and revealed using an UV lamp (254 nm for fluorescent compounds). Flash Column chromatography was carried out using an Interchim Puriflash<ce:sup loc="post">®</ce:sup> 4100 medium pressure preparative chromatography apparatus on silica gel (Bonna-Agela<ce:sup loc="post">®</ce:sup> flash silica, 40–60 μm, 60 Å).</ce:para>
                     <ce:para id="p0160" view="all">We obtained the truncated human FAK(PTK2) [376–1052(end) amino acids of accession number <ce:inter-ref xlink:href="ncbi-p:NP_722560.1" id="intref0015" xlink:type="simple">NP_722560.1</ce:inter-ref>] from Carna Biosciences, Inc. The matching HTRF<ce:sup loc="post">®</ce:sup> KinEASE™-TK kit used in the FAK inhibitory assay was purchased from Cisbio Biosciences, Inc.</ce:para>
                     <ce:para id="p0165" view="all">The [<ce:sup loc="post">18</ce:sup>F]fluoride used for radiosynthesis was produced by the <ce:sup loc="pre">18</ce:sup>O(p, n)<ce:sup loc="post">18</ce:sup>F nuclear reaction by irradiation on 97% enriched H<ce:inf loc="post">2</ce:inf>
                        <ce:sup loc="post">18</ce:sup>O at Nuclear Medicine Department of Peking Cancer Hospital (Beijing, China). QMA light ion-exchange cartridges and C-18 light Sep-Pak<ce:sup loc="post">®</ce:sup> cartridges were obtained from Waters (Milford, MA). Waters Sep-Pak<ce:sup loc="post">®</ce:sup> Accell™ Plus QMA Plus Light Cartridges (130 mg Sorbent per Cartridge, 37–55 μm Particle Size) were preconditioned with 1 N NaHCO<ce:inf loc="post">3</ce:inf> (10 mL), followed by deionized water (10 mL), and Waters Sep-Pak<ce:sup loc="post">®</ce:sup> C18 Plus Light Cartridges (130 mg Sorbent per Cartridge, 55–105 μm Particle Size) were preconditioned with methanol (10 mL) and deionized water (10 mL) before use. Radiopharmaceutical HPLC purification and their radiochemical purity determination was performed on a Shimadzu<ce:sup loc="post">®</ce:sup> LC-20AT HPLC instrument equipped with a SPD-20A UV detector (λ = 254 nm) and Bioscan<ce:sup loc="post">®</ce:sup> flow count 3200 NaI/PMT γ-radiation scintillation detector. Radiopharmaceutical HPLC separations were carried out on a Inertsil<ce:sup loc="post">®</ce:sup> ODS-3 C18 reverse phase semi-preparative column (GL Sciences, Inc. 5 μm, 10 mm × 250 mm), and elution was with a binary gradient system at a flow rate of 2.0 mL/min. Their radiochemical purity determination were achieved on a Kromasil<ce:sup loc="post">®</ce:sup> 100-5C18 reverse phase column (AkzoNobel, 5 μm, 4.6 mm × 250 mm), and elution was with a binary gradient system at a flow rate of 2.0 mL/min.</ce:para>
                     <ce:para id="p0170" view="all">S180 ascites sarcoma mice were purchased from Beijing Vitalriver Animal Technology Co.,Ltd., and normal ICR mice (20–25 g, female) were provided by Beijing Xinglong Animal Technology Co.,Ltd. The <ce:sup loc="pre">18</ce:sup>F radioactivity of the tissues and organs of interest was measured on a PerkinElmer<ce:sup loc="post">®</ce:sup> 2480 WIZARD<ce:sup loc="post">2</ce:sup> automatic gamma counter. The microPET imaging was performed on a SuperArgus PET/CT, which was designed and manufactured by SEDECAL (Sociedad Española de Electromedicina y Calidad, S.A.). All protocols requiring the use of mice were approved by the Animal Care Committee of Beijing Normal University.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0095">Chemistry</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0100">5-Bromo-2-chloro-<ce:italic>N</ce:italic>-(4-methoxyphenyl)pyrimidin-4-amine <ce:bold>(6)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0175" view="all">To the solution of 5-bromo-2,4-dichloropyrimidine <ce:bold>4</ce:bold> (22.79 g, 100.00 mmol) in i-PrOH (200 mL) was added 4-methoxyphenyl amine <ce:bold>5</ce:bold> (18.47 g, 150.00 mmol). After a few minutes, the first batch of gray solid was precipitated out of the reaction mixture. After filtration, a solution of K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (41.46 g, 300.00 mmol) in water (200 mL) was added to the filtrate, and the reaction mixture was stirred at room temperature until all of the 5-bromo-2,4-dichloropyrimidine <ce:bold>4</ce:bold> was consumed completely. The resulting second batch of precipitant was filtered and the filter cake was washed with water and ethyl acetate. After desiccation, the two batches of precipitant were combined to gain the 5-bromo-2-chloro-<ce:italic>N</ce:italic>-(4-methoxyphenyl)pyrimidin-4-amine <ce:bold>6</ce:bold> as a gray solid (16.17 g, 51.4%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 8.25 (s, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 7.17 (brs, 1H), 6.93 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 3.83 (s, 3H); ESI-MS: calcd for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">9</ce:inf>BrClN<ce:inf loc="post">3</ce:inf>O ([M+H]<ce:sup loc="post">+</ce:sup>) 314.0, found 314.0 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0105">2-(4-((5-bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethyl 4-methylbenzenesulfonate <ce:bold>(8a)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0180" view="all">A mixture of <ce:bold>7a</ce:bold> (1.48 g, 4.03 mmol, 1.5 equiv) and <ce:italic>p</ce:italic>-toluenesulfonic acid (PTSA, 0.18 g, 1.07 mmol, 0.4 equiv) was added to the solution of <ce:bold>6</ce:bold> (0.85 g, 2.69 mmol) in 1,4-dioxane (10 mL), and the mixture was stirred at 100 °C for 4 h. After completion of the reaction monitored by TLC, the reaction mixture was quenched with saturated aqueous solution of sodium bicarbonate, extracted with ethyl acetate. After dried with sodium sulfate and filtration, the extract was concentrated <ce:italic>in vacuo</ce:italic>. The residue was purified by column chromatography (petroleum ether/AcOEt, 2/1 to 1/1) to give <ce:bold>8a</ce:bold> as a brownish red solid (0.44 g, 25.3%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 8.05 (s, 1H), 7.80 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.40 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 2H), 7.32 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 6.70 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 4.29 (t, <ce:italic>J</ce:italic> = 4.6 Hz, 2H), 4.12 (t, <ce:italic>J</ce:italic> = 4.5 Hz, 2H), 3.83 (s, 3H), 3.59 (s, 6H), 2.44 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.71, 157.92, 157.24, 153.07, 153.00, 145.52, 135.06, 134.70, 132.79, 130.65, 128.17, 121.18, 114.77, 102.13, 92.81, 69.70, 66.12, 56.22, 55.65, 21.58; ESI-MS: calcd for C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>BrN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">7</ce:inf>S ([M+H]<ce:sup loc="post">+</ce:sup>) 645.1, found 644.8 (C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>BrN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">7</ce:inf>S, [M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0110">2-(2-(4-((5-bromo-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)phenoxy)ethoxy)-ethyl 4-methylbenzenesulfonate <ce:bold>(8b)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0185" view="all">The same reaction as described above to prepare <ce:bold>8a</ce:bold> was used, and <ce:bold>8b</ce:bold> was obtained as a light yellow solid (0.43 g, 26.9%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 8.02 (s, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.39 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 2H), 7.31 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 6.87 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 6.69 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 4.28 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 4.10 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 3.98 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 1H), 3.91 (t, <ce:italic>J</ce:italic> = 4.7 Hz, 1H), 3.83 (s, 3H), 3.78 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 1H), 3.66 (t, <ce:italic>J</ce:italic> = 4.5 Hz, 1H), 3.59 (s, 6H), 2.44 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.73, 157.89, 157.24, 153.75, 152.99, 145.38, 135.07, 134.67, 134.21, 132.93, 130.60, 128.12, 121.30, 114.61, 102.10, 92.72, 70.47, 69.46, 68.53, 67.67, 56.21, 55.61, 21.57; ESI-MS: calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">33</ce:inf>BrN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">8</ce:inf>S ([M+H]<ce:sup loc="post">+</ce:sup>) 689.1, found 689.0 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0115">2-(2-(2-(4-((5-bromo-4-((4-methoxyphenyl)amino)- pyrimidin-2-yl)amino)phenoxy)ethoxy)-ethoxy)ethyl 4-methylbenzenesulfonate <ce:bold>(8c)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0190" view="all">The same reaction as described above to prepare 8a was used, and 8c was obtained as a light yellow solid (0.52 g, 20.4%). <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl3, <ce:italic>δ</ce:italic> ppm): 7.91 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.23–7.33 (m, 4H), 6.83 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.73 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 2H), 4.07 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 3.80 (s, 3H), 3.62–3.71 (m, 10H), 3.54 (s, 6H), 2.38 (s, 3H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.30, 157.89, 157.24, 153.92, 152.97, 145.23, 135.30, 134.62, 134.31, 132.89, 130.69, 128.11, 121.27, 114.69, 102.04, 92.67, 70.89, 70.73, 70.45, 70.01, 68.72, 67.04, 56.32, 55.67, 21.58; ESI-MS: calcd for C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">33</ce:inf>BrN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">8</ce:inf>S ([M+H]<ce:sup loc="post">+</ce:sup>) 733.1, found 733.3 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title id="sectitle0120">5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-fluoroethoxy)phenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxy- <ce:italic>phenyl)pyrimidine-2,4-diamine</ce:italic> ([<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>)</ce:section-title>
                        <ce:para id="p0195" view="all">To a solution of <ce:bold>8a</ce:bold> (20 mg, 0.03 mmol) in anhydrous acetonitrile was added the mixture of KF (9 mg, 0.15 mmol, 5.0 equiv) and Kryptofix 2. 2. 2. (23 mg, 0.06 mmol, 2.0 equiv) and the mixture was stirred in the digestion high-pressure tank at 100 °C for 15 min. Then the reaction mixture was quenched with water and extracted with ethyl acetate. After dried with sodium sulfate and filtration, the extract was concentrated <ce:italic>in vacuo</ce:italic>. The residue was purified by flash column chromatography (petroleum ether/AcOEt, 1/1) to give [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold> as a pale brown solid (14 mg, 91.8%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 8.04 (s, 1H), 7.38 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 6.88 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 6.69 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 4.27 (t, <ce:italic>J</ce:italic> = 4.4 Hz, 2H), 4.11 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 3.82 (s, 3H), 3.57 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.74, 157.93, 157.24, 153.51, 152.99, 135.07, 134.67, 134.47, 121.33, 114.74, 102.11, 92.78, 83.58, 81.91, 67.87, 67.68, 56.21, 55.61; ESI-MS: calcd for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">22</ce:inf>BrFN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">4</ce:inf> ([M+H]<ce:sup loc="post">+</ce:sup>) 493.1, found 493.2 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title id="sectitle0125">5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-(2-fluoroethoxy)ethoxy)phenyl)-N<ce:sup loc="post">4</ce:sup>-(4-methoxyphenyl)pyrimidine-2,4-diamine <ce:bold>(</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>2)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0200" view="all">The same reaction as described above to prepare [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold> was used, and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> was obtained as a pale brown solid (13 mg, 82.3%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 8.05 (s, 1H), 7.36 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 6.86 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 6.71 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 4.27 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 4.13 (t, <ce:italic>J</ce:italic> = 4.3 Hz, 2H), 3.98 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 1H), 3.91 (t, <ce:italic>J</ce:italic> = 4.7 Hz, 1H), 3.83 (s, 3H), 3.76 (t, <ce:italic>J</ce:italic> = 4.1 Hz, 1H), 3.67 (t, <ce:italic>J</ce:italic> = 4.3 Hz, 1H), 3.57 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.76, 157.93, 157.23, 153.80, 152.99, 135.07, 134.67, 134.21, 121.32, 114.63, 102.10, 92.70, 84.39, 82.74, 70.41, 70.22, 69.58, 67.78, 56.21, 55.60; ESI-MS: calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">26</ce:inf>BrFN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">5</ce:inf> ([M+H]<ce:sup loc="post">+</ce:sup>) 537.1, found 537.2 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.7" view="all">
                        <ce:label>4.2.7</ce:label>
                        <ce:section-title id="sectitle0130">5-Bromo-N<ce:sup loc="post">2</ce:sup>-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)phenyl)<ce:italic>N</ce:italic>
                           <ce:sup loc="post">
                              <ce:italic>4</ce:italic>
                           </ce:sup>
                           <ce:italic>-(4-methoxyphenyl)-pyrimidine-2,4-diamine</ce:italic> 
                           <ce:bold>(</ce:bold>[<ce:sup loc="post">19</ce:sup>F]<ce:bold>3)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0205" view="all">The same reaction as described above to prepare [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold> was used, and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> was obtained as a pale brown solid (15 mg, 95.7%). <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>, <ce:italic>δ</ce:italic> ppm): 7.90 (s, 1H), 7.36 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.80 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 4.23 (t, <ce:italic>J</ce:italic> = 4.2 Hz, 2H), 3.85 (s, 3H), 3.64–3.74 (m, 10H), 3.57 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (100 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>, <ce:italic>δ</ce:italic> ppm): 158.79, 157.93, 157.27, 153.87, 152.97, 135.06, 134.67, 134.32, 121.32, 114.67, 102.11, 92.71, 84.67, 82.97, 71.08, 70.63, 70.44, 70.31, 69.61, 67.03, 56.22, 55.63; ESI-MS: calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">30</ce:inf>BrFN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">6</ce:inf> ([M+H]<ce:sup loc="post">+</ce:sup>) 581.1, found 581.3 ([M+H]<ce:sup loc="post">+</ce:sup>).</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0135">Radiolabeling</ce:section-title>
                     <ce:para id="p0210" view="all">[<ce:sup loc="post">18</ce:sup>F]Fluoride trapped on a QMA cartridge (preconditioned as those described in section <ce:cross-ref refid="sec4.1" id="crosref0290">4.1</ce:cross-ref>) was eluted to a digestion high-pressure tank with 1.5 mL of (Kryptofix 2. 2. 2.)/K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> solution (a mixture of 13.5 mg of Kryptofix 2. 2. 2. in 1.25 mL CH<ce:inf loc="post">3</ce:inf>CN and 1.7 mg K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> in 0.25 mL H<ce:inf loc="post">2</ce:inf>O). The solvent was removed at 100 °C under a stream of nitrogen gas. Then, the residue was azeotropically dried with 0.5 mL of anhydrous CH<ce:inf loc="post">3</ce:inf>CN for three times at 100 °C under a stream of nitrogen gas <ce:cross-ref refid="bib63" id="crosref0295">[63]</ce:cross-ref>.</ce:para>
                     <ce:para id="p0215" view="all">For [<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold>, a solution of the tosylate precursors <ce:bold>13a</ce:bold>, <ce:bold>13b</ce:bold>, and <ce:bold>13c</ce:bold> (3.0 mg) in anhydrous CH<ce:inf loc="post">3</ce:inf>CN (0.5 mL) was added to the above digestion high-pressure tank containing the dry Kryptofix 2. 2. 2./[<ce:sup loc="post">18</ce:sup>F] KF complex, respectively. The mixture was heated at 100 °C for 15 min. Deionized water (10 mL) was added, and the mixture was passed through a Sep-Pak C18 cartridge (activated as those described in section <ce:cross-ref refid="sec4.1" id="crosref0300">4.1</ce:cross-ref>), and the Sep-Pak C18 cartridge was washed with deionized water (10 mL) again to remove most of the unreacted free [<ce:sup loc="post">18</ce:sup>F]fluoride. Then the organic phase absorbed on the Sep-Pak C18 cartridge was eluted with 2 mL of CH<ce:inf loc="post">3</ce:inf>CN for two times. After the solvent was removed <ce:italic>in vacuo</ce:italic>, the residue was dissolved in 0.4 mL CH<ce:inf loc="post">3</ce:inf>CN and subjected to HPLC for purification (the composition of mobile phase: CH<ce:inf loc="post">3</ce:inf>CN/H<ce:inf loc="post">2</ce:inf>O = 80/20; HPLC instrument, HPLC column and flow rate were described in section <ce:cross-ref refid="sec4.1" id="crosref0305">4.1</ce:cross-ref>). The radiochemical yield was 7–13% in a total synthesis time of about 60 min (decay not corrected). The radiochemical purity of all tracers was greater than 98%.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0140">Partition coefficient determination <ce:cross-ref refid="bib64" id="crosref0310">[64]</ce:cross-ref>
                     </ce:section-title>
                     <ce:para id="p0220" view="all">The determination of partition coefficients of radiotracers was carried out according to the following procedure: First, the same volume of <ce:italic>n-</ce:italic>octanol and PBS (phosphate buffer saline, 0.05 M, pH 7.4) had been mixed, and each phase had been presaturated with the opposite phase overnight before use.</ce:para>
                     <ce:para id="p0225" view="all">Then, to a centrifuge tube was added a solution of <ce:sup loc="pre">18</ce:sup>F labeled tracer (370 KBq, 10 μCi) in 0.1 mL normal saline, 0.9 mL PBS (presaturated with the opposite phase overnight) and 1.0 mL <ce:italic>n-</ce:italic>octanol (presaturated with the opposite phase overnight) in sequence. The centrifuge tube was vortexed for 0.5–1.0 min at room temperature, followed by centrifugation for 5 min at 5000 rpm. After standing for a while, two samples transferred from the <ce:italic>n-</ce:italic>octanol (100 μL) and PBS (100 μL) layers to counting tubes were measured in a gamma counter. The partition coefficient was expressed as the logarithm of the ratio of the radioactivity from the <ce:italic>n-</ce:italic>octanol phase versus the PBS phase. The measurement was done in triplicate and repeated three times.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0145">In vitro stability studies</ce:section-title>
                     <ce:para id="p0230" view="all">[<ce:sup loc="post">18</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, and [<ce:sup loc="post">18</ce:sup>F]<ce:bold>3</ce:bold> (370 KBq, 10 μCi) after HPLC purification was dissolved in 100 μL of normal saline, and then mixed with 500 μL of normal saline at 37 °C for 1 h and 2 h, respectively. About 100 μL of the solution was analyzed by radio-HPLC (HPLC analysis condition was described in the above section <ce:cross-ref refid="sec4.1" id="crosref0315">4.1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0235" view="all">The <ce:italic>in vitro</ce:italic> stability of the <ce:sup loc="pre">18</ce:sup>F labeled tracers in mouse plasma was determined as following procedure: (1). Incubate 370 KBq the HPLC-purified radiotracers in 100 μL of normal saline with 500 μL of murine plasma at 37 °C for 1 h and 2 h, respectively; (2). After centrifugating the plasma proteins at 5000 rpm for 5 min at 4 °C, they were precipitated by adding 200 μL of acetonitrile. The supernatant was collected. Approximately 100 μL of the supernatant solution was loaded onto HPLC.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0150">FAK inhibitory assay and biochemical assay for kinase selectivity profiling</ce:section-title>
                     <ce:para id="p0240" view="all">The inhibition tests of the F-19 standards [<ce:sup loc="post">19</ce:sup>F]<ce:bold>1</ce:bold>, [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold>, and [<ce:sup loc="post">19</ce:sup>F]<ce:bold>3</ce:bold> against FAK were performed, and the F-19 standard [<ce:sup loc="post">19</ce:sup>F]<ce:bold>2</ce:bold> was profiled against a panel of five kinds of kinases (PYK2, JAK2, IGF-1R, EGFR and PDGFRβ) using the HTRF<ce:sup loc="post">®</ce:sup> (Homogeneous Time-Resolved Fluorescence Methodologies) kinEASE™-TK kit.</ce:para>
                     <ce:para id="p0245" view="all">First, the preparation of the working solutions were carried out: (1) For the FAK inhibitory assay and the kinase selectivity profiling assay against JAK2 and PDGFRβ: The kinase buffer (30000 μL) was prepared by diluting the 5x Enzymatic buffer (including HEPES 250 mM (pH7.0), NaN<ce:inf loc="post">3</ce:inf> 0.1%, BSA 0.05%, Orthovanadate 0.5 mM) (6000 μL) from the HTRF<ce:sup loc="post">®</ce:sup> kinEASE™-TK kit with the distilled water (23250 μL), the MgCl<ce:inf loc="post">2</ce:inf> (5 mM in distilled water, 150 μL), the DTT (1 mM in distilled water, 300 μL), and the SEB (Supplement Enzymatic Buffer from the HTRF<ce:sup loc="post">®</ce:sup> kinEASE™-TK kit, 25 mM in distilled water, 300 μL); For the kinase selectivity profiling assay against PYK2: The kinase buffer (3000 μL) was prepared by diluting the above 5x Enzymatic buffer (600 μL) with the distilled water (2325 μL), the MgCl<ce:inf loc="post">2</ce:inf> (5 mM in distilled water, 15 μL), the DTT (1 mM in distilled water, 30 μL), and the SEB (50 mM in distilled water, 30 μL); For the kinase selectivity profiling assay against EGFR: The kinase buffer (3000 μL) was prepared by diluting the above 5x Enzymatic buffer (600 μL) with the distilled water (2355 μL), the MgCl<ce:inf loc="post">2</ce:inf> (5 mM in distilled water, 15 μL), and the DTT (1 mM in distilled water, 30 μL); For the kinase selectivity profiling assay against IGF-1R: The kinase buffer (5000 μL) was prepared by diluting the above 5x Enzymatic buffer (1000 μL) with the distilled water (3965 μL), the MgCl<ce:inf loc="post">2</ce:inf> (5 mM in distilled water, 25 μL), the MnCl<ce:inf loc="post">2</ce:inf> (1 mM in distilled water, 5 μL), and the DTT (1 mM in distilled water, 5 μL); (2) the HTRF<ce:sup loc="post">®</ce:sup> Detection buffer (HEPES 50 mM (pH7.0) with additives) (1 vial of 200 mL) from the HTRF<ce:sup loc="post">®</ce:sup> kinEASE™-TK kit was ready to use; (3) The compounds working solution which had 2.5X the required final concentration for the enzymatic step was prepared by diluting the above compound stock solution with kinase buffer; (4) The TK Substrate-biotin working solution which had 5X the required final concentration for the enzymatic step was prepared by diluting the above substrate stock solution (500 μM) with kinase buffer; (5) The kinase working solution which had 5X the required final concentration for the enzymatic step was prepared by diluting the above kinase stock solution (500 μM) with kinase buffer; (6) The ATP working solution which had 5X the required final concentration for the enzymatic step was prepared by diluting the above ATP stock solution (5 mM in HEPES buffer 50 mM) with kinase buffer; (7) The Streptavidin-XL665 working solution which had 4X the required final concentration for the assay was prepared by diluting the above Streptavidin-XL665 stock solution (16.67 μM in streptavidin) with HTRF<ce:sup loc="post">®</ce:sup> detection buffer; (8) The Eu<ce:sup loc="post">3+</ce:sup>-Cryptate labeled TK-antibody working solution for the assay was prepared by diluting the TK Antibody-Cryptate stock solution 1:100 in HTRF<ce:sup loc="post">®</ce:sup> detection buffer.</ce:para>
                     <ce:para id="p0250" view="all">Then, the concentration of the enzyme used in the assay, as well as the enzymatic reaction time and the ATP concentration were optimized before the compound testing.</ce:para>
                     <ce:para id="p0255" view="all">For the FAK inhibitory assay: 4 μL kinase buffer, 2 μL FAK in kinase buffer (0.111 ng/μL, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>), 2 μL saturating TK Substrate-biotin (1 μM, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>) was chosen to be used with 2 μL ATP in kinase buffer (13.8 μM, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>) to be incubated for 50 min at room temperature.</ce:para>
                     <ce:para id="p0260" view="all">For the kinase selectivity profiling assay: 4 μL kinase buffer, 2 μL kinase in kinase buffer (0.037 ng/μL for PYK2, JAK2, IGF-1R, EGFR and PDGFRβ, respectively, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>), 2 μL saturating TK Substrate-biotin (1 μM, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>) was chosen to be used with 2 μL ATP in kinase buffer (3 μM for PYK2, JAK2, EGFR and PDGFRβ, and 1.6 μM for IGF-1R, respectively, which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>) to be incubated for a certain time at room temperature (30 min, 30 min, 40 min, 40 min and 50 min for PYK2, JAK2, IGF-1R, EGFR and PDGFRβ, respectively).</ce:para>
                     <ce:para id="p0265" view="all">Phosphorylation of the TK Substrate-biotin was challenged with serially diluted compounds at 1/2-Log concentrations starting at a top concentration of 100 μM (which was <ce:bold>the final concentration for the enzymatic step (10 μL)</ce:bold>). Each concentration was tested in triplicate.</ce:para>
                     <ce:para id="p0270" view="all">Next, during enzymatic reaction step, 4 μL compounds in kinase buffer and 2 μl TK Substrate-biotin were incubated with 2 μL kinase in kinase buffer and 2 μL ATP in kinase buffer (with the above optimized concentration) was added to start the enzymatic reaction. The mixture was incubated for the above optimized time at room temperature.</ce:para>
                     <ce:para id="p0275" view="all">Finally, the Detection reagents [5 μL Eu<ce:sup loc="post">3+</ce:sup>-Cryptate labeled TK-antibody in HTRF<ce:sup loc="post">®</ce:sup> detection buffer, and 5 μL Steptavidin-XL665 in HTRF<ce:sup loc="post">®</ce:sup> detection buffer (0.125 μM, which was <ce:bold>the final concentration for the assay (20 μL)</ce:bold>] were mixed and added to the reaction system. The TR-FRET signal was proportional to the phosphorylation level and was detected by a plate reader (BMG FS) after incubation for 1 h at room temperature. For each compound, the IC<ce:inf loc="post">50</ce:inf> value was determined from a sigmoid dose-response curve using Graph-Pad Prism (GraphPad Software, San Diego, CA, USA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0155">Biodistribution studies and micro-PET/CT imaging studies in S180-tumor-bearing mice <ce:cross-ref refid="bib65" id="crosref0320">[65]</ce:cross-ref>
                     </ce:section-title>
                     <ce:para id="p0280" view="all">An S180 ascites sarcoma mouse was sacrificed and the ascites was immediately drawn off from the carcass and made into S180 sarcoma cell suspension (diluted four times by the normal saline). Then, the normal ICR mice were inoculated subcutaneously into the right front flank with the diluted ascites sarcoma cell suspension (100 μL per mouse, containing about 5 × 10<ce:sup loc="post">6</ce:sup> tumor cells by cell count).</ce:para>
                     <ce:para id="p0285" view="all">The <ce:italic>in vivo</ce:italic> biodistribution studies could be conducted until the tumors reached a size of 0.5–0.8 cm in diameter (for about one week). A normal saline solution containing the <ce:sup loc="pre">18</ce:sup>F-labeled tracers (370 KBq per 100 μL) was injected via the tail vein for each of the S180 tumor bearing mice. The mice (n = 5 for each time point) were sacrificed at 5, 15, 30, 60 and 120 min post injection. The tissues and organs of interest were anatomized and weighed, and the radioactivity was determined with an automatic γ-counter. The percent dose per gram of wet tissue was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. The values were expressed as mean ± SD (n = 5).</ce:para>
                     <ce:para id="p0290" view="all">For micro-PET/CT imaging study, the S180 tumor bearing mouse was injected intravenously with approximately 3.7 MBq of [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold> in 300 μL normal saline, anesthetized with 1.5% isoflurane in air (about 1.5 mL/min) and fixed near the center of microPET scanner with supine position. Static scans (for 30 min and 60 min, 10-min scans for each time point) were obtained on a SuperArgus micro-PET/CT. Then, the images were reconstructed with the Sedecal Reconstruction software and the images were exported by the MMWKS SUPERARGUS software.</ce:para>
                     <ce:para id="p0295" view="all">For blocking studies in the <ce:italic>in vivo</ce:italic> biodistribution and micro-PET/CT imaging studies, at 1 h prior to the injection of the radiotracer [<ce:sup loc="post">18</ce:sup>F]<ce:bold>2</ce:bold>, a group of mice received PF-562,271 in 5% Gelucire 44/14 in sterile water (Gattefosse) (dose: 33 mg/kg, p.o.).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0160">Virtual calculation</ce:section-title>
                     <ce:section id="sec4.8.1" view="all">
                        <ce:label>4.8.1</ce:label>
                        <ce:section-title id="sectitle0165">Preparation of the initial conformations of ligands for the MD simulations</ce:section-title>
                        <ce:para id="p0300" view="all">The structure of the NVP-TAE226 (<ce:cross-ref refid="fig4" id="crosref0325">Fig. 4</ce:cross-ref>A), which was in the complex with FAK (the RCSB Protein Data Bank (PDB) deposition number of the X-ray single-crystal diffraction structures: 2JKK), was selected as the molecular template for sketching the structures of the F-19 standards in this work. For each of the compounds, the conformations resulting from molecular docking, were served as the initial conformations of ligands for the MD Simulations, after the previous structure sketching, molecular energy minimization, systematic conformational search using the Sybyl-X 1.3 molecular modeling software package (Tripos Associates, St. Louis, MO) <ce:cross-ref refid="bib66" id="crosref0330">[66]</ce:cross-ref>, AM1 optimization on Gaussian 09 <ce:cross-ref refid="bib67" id="crosref0335">[67]</ce:cross-ref> and the molecular docking into the ATP binding site of FAK based on 2JKK.pdb with AutoDock 4.0.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.8.2" view="all">
                        <ce:label>4.8.2</ce:label>
                        <ce:section-title id="sectitle0170">MD simulations</ce:section-title>
                        <ce:para id="p0305" view="all">The standard Amber FF03 force field was selected for proteins <ce:cross-ref refid="bib68" id="crosref0340">[68]</ce:cross-ref>, while ligand charges and parameters were determined with the <ce:italic>antechamber</ce:italic> module of Amber 10 <ce:cross-ref refid="bib69" id="crosref0345">[69]</ce:cross-ref> based on the AM1-BCC charge scheme <ce:cross-ref refid="bib70" id="crosref0350">[70]</ce:cross-ref> and the general atom force field (GAFF) <ce:cross-ref refid="bib71" id="crosref0355">[71]</ce:cross-ref>. With the <ce:italic>tleap</ce:italic> module, a rectangular box of TIP3P water was used to solvate the complex <ce:cross-ref refid="bib72" id="crosref0360">[72]</ce:cross-ref>, keeping a minimum distance of 10 Å between the solute and each face of the box. By random replacement of water molecules, we added chloride ions to the system until achieving electroneutrality of the system. Then, with the <ce:italic>sander</ce:italic> module, 4000 steps of energy minimization were performed (with 2000 steps using the steepest descent and the other ones with the conjugate gradient algorithm) to remove possible bad contacts. The nonbonded cutoff distance was set to 10 Å. We undertook all the simulations under periodic boundary conditions for constant volume dynamics with a cutoff of 10 Å. For all the bonds involving hydrogen atoms, the SHAKE algorithm <ce:cross-ref refid="bib73" id="crosref0365">[73]</ce:cross-ref> was applied. We set the time step to 2 fs (0.002 ps). Firstly, the minimized systems were gradually heated to 300 K at a Langevin thermostat collision frequency of 2.0 kcal mol<ce:sup loc="post">−1</ce:sup> Å<ce:sup loc="post">−2</ce:sup>. Then, we equilibrated the system for 500 ps, following the MD simulation of 40 ns (40000 ps) with a time step of 2 fs (0.002 ps). The calculation of electrostatic forces utilized the particle-mesh-Ewald method <ce:cross-ref refid="bib74" id="crosref0370">[74]</ce:cross-ref> with default values.</ce:para>
                        <ce:para id="p0310" view="all">After the MD simulations, the root-mean-square deviations (RMSD) between the starting conformations and the ones during the MD simulation as a function of the simulation time, for the complexes (red) and the ligand (blue) in the complexes respectively, were generated by the <ce:italic>ptraj</ce:italic> module of Amber 10 and graphically interpreted by Origin 8.0.</ce:para>
                        <ce:para id="p0315" view="all">In an effort to compare the initial conformations for MD simulations and the ones during the MD simulations to prove the rationality of the MD simulations, we did the clustering analysis: (a) The <ce:italic>ptraj</ce:italic> module of Amber 10 was used to cluster trajectory frames to produce n clusters (generally, n = 4 or 5) with RMS as the distance metric based on the <ce:italic>means</ce:italic> algorithms. Some PDB files were generated for the average and the representative structures from the clusters; (b) We extracted the average or the representative structures from the cluster that with the highest chance of occurrence, and used it as the conformations of the complexes during the MD simulations.</ce:para>
                        <ce:para id="p0320" view="all">The free energies of binding of the F-19 standards to the FAK (ΔG<ce:inf loc="post">bind,calc</ce:inf>) in this study were evaluated using the MM/PBSA method and the <ce:italic>nmode</ce:italic> module of Amber 10, for the 8000<ce:sup loc="post">th</ce:sup>-20000<ce:sup loc="post">th</ce:sup> snapshots extracted from the stable MD trajectory. For each of the molecular species (complex, protein, and ligand), we calculated the free energies of binding as following (“AB” represented the complex, “A” represented the protein and “B” represented the ligand) <ce:cross-ref refid="bib75" id="crosref0375">[75]</ce:cross-ref>:<ce:display>
                              <ce:formula id="ufd1">
                                 <mml:math altimg="si1.gif" overflow="scroll">
                                    <mml:mtable columnalign="left">
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:msub>
                                                <mml:mi>A</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>q</mml:mi>
                                                   <mml:mi>u</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mo>+</mml:mo>
                                             <mml:msub>
                                                <mml:mi>B</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>q</mml:mi>
                                                   <mml:mi>u</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mrow>
                                                <mml:mover accent="true">
                                                   <mml:mo>→</mml:mo>
                                                   <mml:mrow>
                                                      <mml:mi>Δ</mml:mi>
                                                      <mml:msub>
                                                         <mml:mi>G</mml:mi>
                                                         <mml:mrow>
                                                            <mml:mi>b</mml:mi>
                                                            <mml:mi>i</mml:mi>
                                                            <mml:mi>n</mml:mi>
                                                            <mml:mi>d</mml:mi>
                                                            <mml:mi>i</mml:mi>
                                                            <mml:mi>n</mml:mi>
                                                            <mml:mi>g</mml:mi>
                                                            <mml:mo>,</mml:mo>
                                                            <mml:mi>c</mml:mi>
                                                            <mml:mi>a</mml:mi>
                                                            <mml:mi>l</mml:mi>
                                                            <mml:mi>c</mml:mi>
                                                         </mml:mrow>
                                                      </mml:msub>
                                                   </mml:mrow>
                                                </mml:mover>
                                             </mml:mrow>
                                             <mml:mi>A</mml:mi>
                                             <mml:msub>
                                                <mml:mi>B</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>q</mml:mi>
                                                   <mml:mi>u</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:msub>
                                                <mml:mo>↓</mml:mo>
                                                <mml:mrow>
                                                   <mml:mo>-</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mtext>so</mml:mtext>
                                                         <mml:mi>l</mml:mi>
                                                         <mml:mi>v</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:msubsup>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mspace width="0.5em"/></mml:mspace>
                                             <mml:msub>
                                                <mml:mo>↓</mml:mo>
                                                <mml:mrow>
                                                   <mml:mo>-</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mtext>s</mml:mtext>
                                                         <mml:mi>o</mml:mi>
                                                         <mml:mi>l</mml:mi>
                                                         <mml:mi>v</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:msubsup>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mspace width="1em"/></mml:mspace>
                                             <mml:mspace width="1em"/></mml:mspace>
                                             <mml:mspace width="1em"/></mml:mspace>
                                             <mml:mspace width="1em"/></mml:mspace>
                                             <mml:msub>
                                                <mml:mo>↓</mml:mo>
                                                <mml:mrow>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mtext>s</mml:mtext>
                                                         <mml:mi>o</mml:mi>
                                                         <mml:mi>l</mml:mi>
                                                         <mml:mi>v</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mrow>
                                                         <mml:mi>A</mml:mi>
                                                         <mml:mi>B</mml:mi>
                                                      </mml:mrow>
                                                   </mml:msubsup>
                                                </mml:mrow>
                                             </mml:msub>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:msub>
                                                <mml:mi>A</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>g</mml:mi>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>s</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mo>+</mml:mo>
                                             <mml:msub>
                                                <mml:mi>B</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>g</mml:mi>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>s</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mrow>
                                                <mml:mover accent="true">
                                                   <mml:mo>→</mml:mo>
                                                   <mml:mrow>
                                                      <mml:mi>Δ</mml:mi>
                                                      <mml:msub>
                                                         <mml:mi>G</mml:mi>
                                                         <mml:mrow>
                                                            <mml:mi>g</mml:mi>
                                                            <mml:mi>a</mml:mi>
                                                            <mml:mi>s</mml:mi>
                                                         </mml:mrow>
                                                      </mml:msub>
                                                   </mml:mrow>
                                                </mml:mover>
                                             </mml:mrow>
                                             <mml:mspace width="1em"/></mml:mspace>
                                             <mml:mi>A</mml:mi>
                                             <mml:msub>
                                                <mml:mi>B</mml:mi>
                                                <mml:mrow>
                                                   <mml:mtext>gas</mml:mtext>
                                                </mml:mrow>
                                             </mml:msub>
                                          </mml:mtd>
                                       </mml:mtr>
                                    </mml:mtable>
                                 </mml:math>
                              </ce:formula>
                           </ce:display>
                           <ce:display>
                              <ce:formula id="ufd2">
                                 <mml:math altimg="si2.gif" overflow="scroll">
                                    <mml:mtable>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msub>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>b</mml:mi>
                                                   <mml:mi>i</mml:mi>
                                                   <mml:mi>n</mml:mi>
                                                   <mml:mi>d</mml:mi>
                                                   <mml:mi>i</mml:mi>
                                                   <mml:mi>n</mml:mi>
                                                   <mml:mi>g</mml:mi>
                                                   <mml:mo>,</mml:mo>
                                                   <mml:mi>c</mml:mi>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>l</mml:mi>
                                                   <mml:mi>c</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mo>=</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msub>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>g</mml:mi>
                                                   <mml:mi>a</mml:mi>
                                                   <mml:mi>s</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>s</mml:mi>
                                                   <mml:mi>o</mml:mi>
                                                   <mml:mi>l</mml:mi>
                                                   <mml:mi>v</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>A</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>s</mml:mi>
                                                   <mml:mi>o</mml:mi>
                                                   <mml:mi>l</mml:mi>
                                                   <mml:mi>v</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>B</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>+</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>s</mml:mi>
                                                   <mml:mi>o</mml:mi>
                                                   <mml:mi>l</mml:mi>
                                                   <mml:mi>v</mml:mi>
                                                </mml:mrow>
                                                <mml:mrow>
                                                   <mml:mi>A</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                </mml:mrow>
                                             </mml:msubsup>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>=</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>H</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>g</mml:mi>
                                                      <mml:mi>a</mml:mi>
                                                      <mml:mi>s</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>-</mml:mo>
                                                <mml:mtext>T</mml:mtext>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>S</mml:mi>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>A</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>B</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>+</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mrow>
                                                   <mml:mi>A</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                </mml:mrow>
                                             </mml:msubsup>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>≈</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>g</mml:mi>
                                                      <mml:mi>a</mml:mi>
                                                      <mml:mi>s</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>-</mml:mo>
                                                <mml:mtext>T</mml:mtext>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>S</mml:mi>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>A</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>-</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mi>B</mml:mi>
                                             </mml:msubsup>
                                             <mml:mo>+</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msubsup>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                                <mml:mrow>
                                                   <mml:mi>A</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                </mml:mrow>
                                             </mml:msubsup>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>=</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mtext>e</mml:mtext>
                                                      <mml:mi>l</mml:mi>
                                                      <mml:mi>e</mml:mi>
                                                      <mml:mi>c</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>r</mml:mi>
                                                      <mml:mi>o</mml:mi>
                                                      <mml:mi>s</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>a</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                      <mml:mi>c</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>v</mml:mi>
                                                      <mml:mi>d</mml:mi>
                                                      <mml:mi>W</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>int</mml:mi>
                                                      <mml:mi>r</mml:mi>
                                                      <mml:mi>a</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mi>A</mml:mi>
                                                </mml:msubsup>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mi>A</mml:mi>
                                                </mml:msubsup>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mi>B</mml:mi>
                                                </mml:msubsup>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mi>B</mml:mi>
                                                </mml:msubsup>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>+</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msubsup>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msubsup>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mtext>T</mml:mtext>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:mi>S</mml:mi>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>≈</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mtext>e</mml:mtext>
                                                      <mml:mi>l</mml:mi>
                                                      <mml:mi>e</mml:mi>
                                                      <mml:mi>c</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>r</mml:mi>
                                                      <mml:mi>o</mml:mi>
                                                      <mml:mi>s</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>a</mml:mi>
                                                      <mml:mi>t</mml:mi>
                                                      <mml:mi>i</mml:mi>
                                                      <mml:mi>c</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>v</mml:mi>
                                                      <mml:mi>d</mml:mi>
                                                      <mml:mi>W</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>+</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>[</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msubsup>
                                                <mml:mo>-</mml:mo>
                                                <mml:mrow>
                                                   <mml:mo>(</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mi>P</mml:mi>
                                                         <mml:mi>B</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:msubsup>
                                                   <mml:mo>+</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mi>P</mml:mi>
                                                         <mml:mi>B</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:msubsup>
                                                   <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                                <mml:mo>]</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>+</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>[</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msubsup>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                   <mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msubsup>
                                                <mml:mo>-</mml:mo>
                                                <mml:mrow>
                                                   <mml:mo>(</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mi>S</mml:mi>
                                                         <mml:mi>A</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:msubsup>
                                                   <mml:mo>+</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msubsup>
                                                      <mml:mi>G</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mi>S</mml:mi>
                                                         <mml:mi>A</mml:mi>
                                                      </mml:mrow>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:msubsup>
                                                   <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                                <mml:mo>]</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mtext>T</mml:mtext>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:mi>S</mml:mi>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>=</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>[</mml:mo>
                                                <mml:mrow>
                                                   <mml:mo>(</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msub>
                                                      <mml:mi>E</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mtext>e</mml:mtext>
                                                         <mml:mi>l</mml:mi>
                                                         <mml:mi>e</mml:mi>
                                                         <mml:mi>c</mml:mi>
                                                         <mml:mi>t</mml:mi>
                                                         <mml:mi>r</mml:mi>
                                                         <mml:mi>o</mml:mi>
                                                         <mml:mi>s</mml:mi>
                                                         <mml:mi>t</mml:mi>
                                                         <mml:mi>a</mml:mi>
                                                         <mml:mi>t</mml:mi>
                                                         <mml:mi>i</mml:mi>
                                                         <mml:mi>c</mml:mi>
                                                      </mml:mrow>
                                                   </mml:msub>
                                                   <mml:mo>+</mml:mo>
                                                   <mml:mi>Δ</mml:mi>
                                                   <mml:msub>
                                                      <mml:mi>E</mml:mi>
                                                      <mml:mrow>
                                                         <mml:mi>v</mml:mi>
                                                         <mml:mi>d</mml:mi>
                                                         <mml:mi>W</mml:mi>
                                                      </mml:mrow>
                                                   </mml:msub>
                                                   <mml:mo>)</mml:mo>
                                                </mml:mrow>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>]</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mtext>T</mml:mtext>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:mi>S</mml:mi>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>=</mml:mo>
                                             <mml:mrow>
                                                <mml:mo>(</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>E</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mtext>gas</mml:mtext>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>P</mml:mi>
                                                      <mml:mi>B</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>+</mml:mo>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:mi>Δ</mml:mi>
                                                <mml:msub>
                                                   <mml:mi>G</mml:mi>
                                                   <mml:mrow>
                                                      <mml:mi>S</mml:mi>
                                                      <mml:mi>A</mml:mi>
                                                   </mml:mrow>
                                                </mml:msub>
                                                <mml:mo>)</mml:mo>
                                             </mml:mrow>
                                             <mml:mo>-</mml:mo>
                                             <mml:mtext>T</mml:mtext>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:mi>S</mml:mi>
                                          </mml:mtd>
                                       </mml:mtr>
                                       <mml:mtr>
                                          <mml:mtd>
                                             <mml:mo>=</mml:mo>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:msub>
                                                <mml:mi>G</mml:mi>
                                                <mml:mrow>
                                                   <mml:mi>M</mml:mi>
                                                   <mml:mi>M</mml:mi>
                                                   <mml:mi>P</mml:mi>
                                                   <mml:mi>B</mml:mi>
                                                   <mml:mi>S</mml:mi>
                                                   <mml:mi>A</mml:mi>
                                                </mml:mrow>
                                             </mml:msub>
                                             <mml:mo>-</mml:mo>
                                             <mml:mtext>T</mml:mtext>
                                             <mml:mi>Δ</mml:mi>
                                             <mml:mi>S</mml:mi>
                                          </mml:mtd>
                                       </mml:mtr>
                                    </mml:mtable>
                                 </mml:math>
                              </ce:formula>
                           </ce:display>
                        </ce:para>
                        <ce:para id="p0325" view="all">In the equation aboved, ΔG<ce:inf loc="post">gas</ce:inf> was the interaction energy between A and B in the gas phase; ΔG<ce:inf loc="post">solv</ce:inf>
                           <ce:sup loc="post">A</ce:sup>, ΔG<ce:inf loc="post">solv</ce:inf>
                           <ce:sup loc="post">B</ce:sup>, and ΔG<ce:inf loc="post">solv</ce:inf>
                           <ce:sup loc="post">AB</ce:sup> were the solvation free energies of A, B, and AB respectively, which were estimated using a continuum approach (Poisson−Boltzmann/surface area), i.e., ΔG<ce:inf loc="post">solv</ce:inf>
                           <ce:sup loc="post">AB</ce:sup> = ΔG<ce:inf loc="post">PBSA</ce:inf>
                           <ce:sup loc="post">AB</ce:sup> = ΔG<ce:inf loc="post">PB</ce:inf>
                           <ce:sup loc="post">AB</ce:sup> + ΔG<ce:inf loc="post">SA</ce:inf>
                           <ce:sup loc="post">AB</ce:sup>, etc.; ΔE<ce:inf loc="post">intra</ce:inf> was internal energy arising from bond, angle and dihedral terms in the MM forcefield (this term always amounted to zero in the single trajectory approach).</ce:para>
                        <ce:para id="p0330" view="all">The binding entropy contributions (translation, rotation, and vibration) were estimated using the <ce:italic>nmode</ce:italic> module of Amber 10. The structural minimizations and normal mode analyses for the complex, protein, and ligand were carried out with a distance-dependent dielectric constant, <ce:italic>ε</ce:italic> = <ce:italic>4r</ce:italic>, and convergence tolerance tighter than RMSD = 10<ce:sup loc="post">−5</ce:sup> kcal mol<ce:sup loc="post">− 1</ce:sup> Å<ce:sup loc="post">− 1</ce:sup>.</ce:para>
                        <ce:para id="p0335" view="all">The ΔG<ce:inf loc="post">bind,exp</ce:inf> (experimental binding free energies) were estimated for the F-19 standards from the experimental IC<ce:inf loc="post">50</ce:inf> values using the following relationship: ΔG<ce:inf loc="post">bind,exp</ce:inf> = RTlnK<ce:inf loc="post">dissociated</ce:inf> = RTln(IC<ce:inf loc="post">50</ce:inf> + 0.5C<ce:inf loc="post">enzyme</ce:inf>) ≈ RTlnIC<ce:inf loc="post">50</ce:inf>, where R was ideal gas constant, T was the temperature in Kelvin (298 K was used in this work), and C<ce:inf loc="post">enzyme</ce:inf> was the concentration of enzyme, which was a very small number after equilibration and could be omitted in most cases.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:section-title id="sectitle0175">Compliance with ethical standards</ce:section-title>
                  <ce:para id="p0340" view="all">All protocols requiring the use of mice were approved by the Animal Care Committee of Beijing Normal University.</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:section-title id="sectitle0180">Author contributions</ce:section-title>
                  <ce:para id="p0345" view="all">Y. Fang performed the drug sign, biological study, some parts of the synthesis of the labeling precursors, all the radiochemical labeling, most of the biological evaluation and the MD simulation; X.-Y. Xu performed some parts of the synthesis of the labeling precursors; D.-W. Wang, J.-P. Liu, A.-Q. Wu, Q.-Q. Xue, H. W. provided some help during the biodistribution study; H.-B. Zhang conducted the whole plan.</ce:para>
               </ce:section>
               <ce:section id="sec7" view="all">
                  <ce:section-title id="sectitle0185">Conflicts of interest</ce:section-title>
                  <ce:para id="p0350" view="all">The authors declare no conflict of interest.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0190">Acknowledgments</ce:section-title>
               <ce:para id="p0355" view="all">This work was supported by the <ce:grant-sponsor id="gs1" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Major Scientific and Technological Special Project</ce:grant-sponsor> for “Significant New Drugs Development” (Grant Nos. <ce:grant-number refid="gs1">2014ZX09507007-001</ce:grant-number> and <ce:grant-number refid="gs1">2014ZX09507007-003</ce:grant-number>); the <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Science and Technology Support Program</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs2">2014BAA03B03</ce:grant-number>) and the <ce:grant-sponsor id="gs3" sponsor-id="http://dx.doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (Grant Nos. <ce:grant-number refid="gs3">21371026</ce:grant-number>). We also thank the Nuclear Medicine Department of Peking Cancer Hospital (Beijing, China) for providing the fluoride-18 nuclide and the use of the Micro-PET/CT.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0195">Supplementary data</ce:section-title>
                  <ce:para id="p0360" view="all">The following is the supplementary data related to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Supporting information</ce:label>
                           <ce:alt-text role="short" id="alttext0015">Supporting information</ce:alt-text>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523417300235/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0200">Supplementary data</ce:section-title>
                  <ce:para id="p0365" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2017.01.015" id="intref0020" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2017.01.015</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0205">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Schaller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Borgman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Cobb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Vines</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Reynolds</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>pp125<ce:sup loc="post">FAK</ce:sup>, A structurally distinctive protein-tyrosine kinase associated with focal adhesions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>89</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5192</sb:first-page>
                              <sb:last-page>5196</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Hanks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Calalb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Harper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>89</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8487</sb:first-page>
                              <sb:last-page>8491</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Schaller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: exploring FAK structure to gain insight into function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. Rev. Cell Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>288</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>185</sb:first-page>
                              <sb:last-page>225</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-L.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: from in vitro studies to functional analyses in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Protein Pept. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>52</sb:first-page>
                              <sb:last-page>67</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Hochwald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FAK as a target for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gene Ther. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>26</sb:first-page>
                              <sb:last-page>35</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Schlaepfer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Mitra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multiple connections link FAK to cell motility and invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Genet. Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>92</sb:first-page>
                              <sb:last-page>101</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Mitra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Hanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Schlaepfer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: in command and control of cell motility</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>56</sb:first-page>
                              <sb:last-page>68</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: the first ten years</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1409</sb:first-page>
                              <sb:last-page>1416</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tomkiewicz-Raulet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Yen-Pon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Camacho-Artacho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lietha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Herbeuval</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Coumoul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Garbay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>237</sb:first-page>
                              <sb:last-page>251</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lietha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS ONE</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e3800</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Whalen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hulford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Autry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Richter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Emerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Martinez-Alsina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lorenzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Berliner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Luzzio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Schmitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>LaGreca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wessel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Marr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Griffor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vajdos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1935</sb:first-page>
                              <sb:last-page>1944</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jarray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-L.</ce:given-name>
                                 <ce:surname>Coq</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lietha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Loukaci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lepelletier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hadj-Slimane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Garbay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4552</sb:first-page>
                              <sb:last-page>4556</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Seenisamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Emmanuvel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Kulkarni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bomke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Rohdich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Greiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Esdar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Krier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Gradler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Musil</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1160</sb:first-page>
                              <sb:last-page>1170</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Hochwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of FAK in tumor metabolism and therapy. Pharmacol</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ther</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>154</sb:first-page>
                              <sb:last-page>163</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Marlowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.D.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>No.pe10</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lechertier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hodivala-Dilke</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase and tumor angiogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>226</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>404</sb:first-page>
                              <sb:last-page>412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of focal adhesion kinase inhibitors in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>638</sb:first-page>
                              <sb:last-page>642</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Iacocca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Roche</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Simkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2417</sb:first-page>
                              <sb:last-page>2423</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.W.</ce:given-name>
                                 <ce:surname>McLean</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.O.</ce:given-name>
                                 <ce:surname>Carragher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Avizienyte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Brunton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Frame</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of focal-adhesion kinase in cancer - a new therapeutic opportunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>505</sb:first-page>
                              <sb:last-page>515</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.A.</ce:given-name>
                                 <ce:surname>Kweh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Histol. Histopathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>503</sb:first-page>
                              <sb:last-page>510</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Chatzizacharias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Kouraklis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Theocharis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin. Ther</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1315</sb:first-page>
                              <sb:last-page>1328</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>McGonigal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of focal adhesion kinase in human cancer: a potential target for drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>681</sb:first-page>
                              <sb:last-page>684</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>van Nimwegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>van de Water</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase: a potential target in cancer therapy. Biochem</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>597</sb:first-page>
                              <sb:last-page>609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase as a cancer therapy target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>735</sb:first-page>
                              <sb:last-page>741</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schultze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fiedler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>777</sb:first-page>
                              <sb:last-page>788</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.-M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting FAK in human cancer: from finding to first clinical trials</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>687</sb:first-page>
                              <sb:last-page>706</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schultze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fiedler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anti-Cancer Agent. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>593</sb:first-page>
                              <sb:last-page>599</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fujii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Koshikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nomoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Okochi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaneko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yatabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Takeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nakao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hepatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104</sb:first-page>
                              <sb:last-page>111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hum. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1384</sb:first-page>
                              <sb:last-page>1390</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-Q.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-J.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase mrna overexpression in hepatocellular carcinoma HCC and correlation thereof with prognosis of HCC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Zhonghua Yi Xue Za Zhi</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1256</sb:first-page>
                              <sb:last-page>1259</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Lark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Livasy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dressler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Millikan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Geradts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Iacocca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Little</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Craven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mod. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1289</sb:first-page>
                              <sb:last-page>1294</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Owens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Craven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Dent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Weiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kornberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpression of the focal adhesion kinase (p125<ce:sup loc="post">FAK</ce:sup>) in invasive human tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2752</sb:first-page>
                              <sb:last-page>2755</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Lightfoot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lark</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Livasy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dressler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Craven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Breast Cancer Res. Treat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>109</sb:first-page>
                              <sb:last-page>116</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Giaginis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vgenopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Tsourouflis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.N.</ce:given-name>
                                 <ce:surname>Politi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Kouraklis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Theocharis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pathol. Oncol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>173</sb:first-page>
                              <sb:last-page>181</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gabriel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hasenburg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Waizenegger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Orlowska-Volk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Stickeler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>zur Hausen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Gynecol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1221</sb:first-page>
                              <sb:last-page>1225</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Recher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ysebaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Beyne-Rauzy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Mansat-De Mas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-B.</ce:given-name>
                                 <ce:surname>Ruidavets</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cariven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Demur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Payrastre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Laurent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Racaud-Sultan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3191</sb:first-page>
                              <sb:last-page>3197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tavernier-Tardy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cornillon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Campos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Flandrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Duval</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nadal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Guyotat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>764</sb:first-page>
                              <sb:last-page>768</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Hecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grammer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Y.</ce:given-name>
                                 <ce:surname>Gillespie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stewart</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Gladson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase enhances signaling through the shc/extracellular signal regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2699</sb:first-page>
                              <sb:last-page>2707</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gutenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Bruck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buchfelder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Ludwig</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of tyrosine kinases FAK and PYK2 in 331 human astrocytomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Neuropathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>224</sb:first-page>
                              <sb:last-page>230</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schroder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Delling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Kaiser</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression analysis of protein tyrosine kinases of the FAK (focal adhesion kinase) family in osteosarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pathologe</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>361</sb:first-page>
                              <sb:last-page>366</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Judson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Van Le</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>86</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1551</sb:first-page>
                              <sb:last-page>1556</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Beierle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Massoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hartwich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.V.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>McGrady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.B.</ce:given-name>
                                 <ce:surname>London</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3299</sb:first-page>
                              <sb:last-page>3305</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Owens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Dent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Sturge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Crave</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Surg. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>100</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tremblay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hauck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Aprikian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Begin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chapdelaine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chevalier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Focal adhesion kinase (pp125<ce:sup loc="post">FAK</ce:sup>) expression, activation and association with paxillin and p50<ce:sup loc="post">CSK</ce:sup> in human metastatic prostate carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>164</sb:first-page>
                              <sb:last-page>171</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Canel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Secades</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Rodrigo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cabanillas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Suarez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-D.</ce:given-name>
                                 <ce:surname>Chiara</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of FAK gene copy number</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11 Pt 1</sb:issue-nr>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3272</sb:first-page>
                              <sb:last-page>3279</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Slack-Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Tilghman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Iwanicki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Ung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Autry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Luzzio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Kath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cellular characterization of a novel focal adhesion kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>282</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14845</sb:first-page>
                              <sb:last-page>14852</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Christopher A.S.</ce:given-name>
                                 <ce:surname>Kalgutkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Bauman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.X.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Soglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Aspnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Kung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Klug-McLeod</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Zawistoski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>McGlynn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Oliver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dunn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Richter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Kath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Hulford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Autry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Luzzio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Ung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Bonnette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Buckbinder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mistry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Griffor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Guzman-Perez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Trifluoromethyl pyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6071</sb:first-page>
                              <sb:last-page>6077</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="bib48a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Francois</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zajac-Kaye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hochwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel focal adhesion kinase inhibitor (PF-04554878) decreases growth and induces apoptosis in pancreatic neuroendocrine tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S174</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib48b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Bendell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bedard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Cleary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pandya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Houk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hosea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Zandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Shreeve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Siu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors, 2011 ASCO Annual Meeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>p abstract 3002</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="bib49a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Richmond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Karanewsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-J.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ohmori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Caldwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2173</sb:first-page>
                              <sb:last-page>2176</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib49b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Richmond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Karanewsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-J.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Che</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Caldwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kanazawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Umemura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Matsuura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ohmori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Honda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2689</sb:first-page>
                              <sb:last-page>2692</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mikolon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Stupack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Schlaepfer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FERM control of FAK function: implications for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2306</sb:first-page>
                              <sb:last-page>2314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Tanjoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Walsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Uryu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tomar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.O.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mielgo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koenig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Biol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>764</sb:first-page>
                              <sb:last-page>777</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Zificsak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Gingrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Breslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Dunn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.K.L.</ce:given-name>
                                 <ce:surname>Milkiewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Theroff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.V.</ce:given-name>
                                 <ce:surname>Thieu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Underiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Aimone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Albom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Saville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Husten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Angeles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Finn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>O'Kane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dobrzanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Dorsey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>133</sb:first-page>
                              <sb:last-page>137</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Siu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Bendell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Cleary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.A.</ce:given-name>
                                 <ce:surname>Razak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Infante</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Pandya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.L.</ce:given-name>
                                 <ce:surname>Bedard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Houk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Shreeve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.I.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1100</sb:first-page>
                              <sb:last-page>1107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.-L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Vidal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Neill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sprott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Keegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Paterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Padval</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Pachter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In the FAK inhibitors VS-4718 and VS-5095 attenuate breast cancer stem cell function in vitro and tumor growth in vivo, AACR 103<ce:sup loc="post">rd</ce:sup> Annual Meeting 2012</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>AM2012-LB-192</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Auger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Smitheman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Korenchuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>McHugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kruger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Van Aller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Smallwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Gontarek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Faitg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In the focal adhesion kinase inhibitor GSK2256098: a potent and selective inhibitor for the treatment of cancer, 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>p abstract 118</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="bib56a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Iwatani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Iwata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Okabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Skene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tomita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Aramaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Hosfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Baba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and characterization of novel allosteric FAK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                              <sb:last-page>60</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib56b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tomita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oomori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Aramaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Matsushita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Iwatani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Iwata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Okabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Awazu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Isono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Skene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Hosfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kawamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bab</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based discovery of cellular-active allosteric inhibitors of FAK</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1779</sb:first-page>
                              <sb:last-page>1785</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nyberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kweh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Magis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ostrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7405</sb:first-page>
                              <sb:last-page>7416</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.V.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Hunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Magis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Ostrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4716</sb:first-page>
                              <sb:last-page>4724</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="bib59a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Ucar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nyberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Massoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Ostrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zajac-Kaye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Hochwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3250</sb:first-page>
                              <sb:last-page>3259</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib59b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Ucar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Magis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-H.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kurenova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zajac-Kaye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Hochwald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting the interaction of cmet and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>602</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.L.</ce:given-name>
                                 <ce:surname>Palma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Magis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ostrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Agents Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>532</sb:first-page>
                              <sb:last-page>545</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Golubovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Magis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Ostrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Morrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Cance</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>342</sb:first-page>
                              <sb:last-page>346</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.-J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>LaFortune</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Honda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ohmori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hatakeyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Groot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.K.A.</ce:given-name>
                                 <ce:surname>Yung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1357</sb:first-page>
                              <sb:last-page>1367</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.-C.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-R.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-P.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-M.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Saji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.-L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of novel <ce:sup loc="post">18</ce:sup>F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9283</sb:first-page>
                              <sb:last-page>9296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of novel F-18 labeled fluoroarylvaline derivatives: potential PET imaging agents for tumor detection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4873</sb:first-page>
                              <sb:last-page>4877</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Dang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of novel F-18 labeled pyrazolo[1,5-a]pyrimidine derivatives: potential PET imaging agents for tumor detection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4736</sb:first-page>
                              <sb:last-page>4741</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref62">
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>Sybyl, Version X 1.3</sb:maintitle>
                              </sb:title>
                              <sb:date>2011</sb:date>
                              <sb:publisher>
                                 <sb:name>Tripos Associates</sb:name>
                                 <sb:location>St.Louis, MO</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Frisch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.W.</ce:given-name>
                                 <ce:surname>Trucks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Schlegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Scuseria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Robb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Cheeseman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Scalmani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Barone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mennucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Petersson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakatsuji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Caricato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Hratchian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Izmaylov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bloino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Sonnenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Toyota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fukuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hasegawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ishida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Honda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kitao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Vreven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Peralta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Ogliaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Bearpark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Heyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Brothers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Kudin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.N.</ce:given-name>
                                 <ce:surname>Staroverov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Normand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Raghavachari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Rendell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Burant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Iyengar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tomasi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cossi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rega</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Millam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Klene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Knox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bakken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Adamo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jaramillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Gomperts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Stratmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Yazyev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Austin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cammi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Pomelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ochterski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Morokuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Zakrzewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Voth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Salvador</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Dannenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dapprich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Daniels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Farkas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.J.B.</ce:given-name>
                                 <ce:surname>Foresman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Ortiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cioslowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>-Gaussian 09, Revision B.01</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2010</sb:date>
                              <sb:publisher>
                                 <sb:name>Gaussian, Inc.</sb:name>
                                 <sb:location>Wallingford, CT</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chowdhury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cieplak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Caldwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kollman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1999</sb:first-page>
                              <sb:last-page>2012</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref65">
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>AMBER, Version 10</sb:maintitle>
                              </sb:title>
                              <sb:date>2008</sb:date>
                              <sb:publisher>
                                 <sb:name>University of California</sb:name>
                                 <sb:location>San Francisco, CA</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jakalian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Jack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.I.</ce:given-name>
                                 <ce:surname>Bayly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fast, efficient generation of high-quality atomic charges.AM1-BCC model: II. Parameterization and validation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1623</sb:first-page>
                              <sb:last-page>1641</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Wolf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Caldwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Kollman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Case</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development and testing of a general amber force field</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1157</sb:first-page>
                              <sb:last-page>1174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.L.</ce:given-name>
                                 <ce:surname>Jorgensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chandrasekhar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Madura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.I.</ce:given-name>
                                 <ce:surname>Roger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparison of simple potential functions for simulating liquid water</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>1983</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>935</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Ryckaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ciccotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.C.</ce:given-name>
                                 <ce:surname>Berendsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1977</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>341</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Essmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Perera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Berkowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Darden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.G.</ce:given-name>
                                 <ce:surname>Pedersen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A smooth particle mesh ewald method</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8577</sb:first-page>
                              <sb:last-page>8593</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Morin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Kollman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5221</sb:first-page>
                              <sb:last-page>5230</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>